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Abstract
Nanotechnology is rapidly developing, and the engineered materials (ENMs)
are utilized in a wide array of end user products owing to their unique physiochemical
properties. Of the various forms of ENMs, silver nanoparticles (AgNPs) have gained
much attention for potential uses in commercial applications. Due to their unique
features, particularly antimicrobial properties, there had been a surge in the production
of AgNPs-based products, hence increasing the potential of both occupational and
consumer exposure. Among the various routes of human exposure, pulmonary
exposure to AgNPs has received increased interest due to their potential to cause
pulmonary injury, cross the alveolar-capillary barrier, and distribute to remote organs.
However, the mechanism by which pulmonary exposure to AgNPs may induce
pathophysiological effects on the cardiovascular system and other major remote organs
(including liver, kidney, spleen and brain) is not well understood. Thus, the primary
objective

of

this

dissertation

was

to

evaluate,

in

mice,

the

coating

[(polyvinylpyrrolidone (PVP) and citrate (CT)], time (1 day and 7-days) and dosedependent (0.05, 0.5 and 5 mg/kg) effects of pulmonary exposure to 10 nm AgNPs, on
the cardiovascular system and other major organs including liver, kidney, spleen and
brain. Moreover, since AgNPs are able to translocate from the airways into the
bloodstream, they can, consequently, interact with circulatory cells such as
erythrocytes. However, information regarding the pathophysiological effects and
possible mechanism of action of AgNPs on the erythrocytes are still inadequately
studied. Hence, to address this, we evaluated the effects of PVP- and CT- AgNPs (10
nm) at three different concentrations (2.5, 10, and 40 µg/ml) on mouse erythrocytes in
vitro. For the in vivo experiments, AgNPs exposure in mice was achieved by single

viii
intra-tracheal instillation and various cardiac and systemic endpoints were assessed
including thrombosis, inflammation, oxidative stress, DNA damage and apoptosis
following 1 and 7-days of exposure. Pulmonary deposited AgNPs induced dosedependent cardiovascular effects including thrombosis, oxidative stress, inflammation,
coagulation and apoptosis, with some of the effects persisting even after 7-days postexposure. A biodistribution of AgNPs showed that, besides the presence of AgNPs in
the lung, these nanoparticles were also found in the spleen, liver and to a lesser extent
in the kidney, heart and brain. In addition, both PVP- and CT- AgNPs induced
inflammation and oxidative stress in these latter organs as evidenced by significant
elevations of tumor necrosis factor α, interleukin-6, glutathione, total antioxidants,
nitric oxide and 8-isoprostane, as well as DNA damage and apoptosis in lung, heart,
liver and brain, as shown by 8-hydroxy-2-deoxyguanosine and TUNEL assay. Our in
vitro study revealed that both coating AgNPs induced significant and dose-dependent
hemolysis, oxidative stress and increase cytosolic Ca2+, annexin V binding and calpain
activity. In conclusion, our data showed that firstly AgNPs deposition in the lungs
induced pulmonary inflammation and oxidative stress. Secondly, the particles
translocated and distributed to the remote organs including heart, liver, kidney, spleen
and brain and caused alteration in oxidative stress markers, inflammatory cytokines,
DNA damage and apoptosis. Thirdly, AgNPs induced prothrombotic actions, and
altered coagulation markers. Fourthly, in vitro data indicated that both PVP- and CTAgNPs induced erythrocyte hemolysis and eryptosis. Overall, these in vivo and in vitro
results, not only reinforced the previously established mechanisms of DNA damage
caused by reactive oxygen species, resulting in cellular dysfunction and apoptosis, but
also provided a novel mechanistic insight into the pathophysiological effects and tissue
distribution of AgNPs following pulmonary exposure.
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األثر الفيزيولوجي – المرضي لمركبات الفضة النانوية على الرئتين واألجهزة األخرى:
تأثيرات وضع طبقة خارجية ،والزمن ،والجرعة
الملخص

تتطور التقانة النانوية بسرعة ،وتستخدم المواد الهندسية في طيف واسع من منتجات المستهلك
النهائي ،ومرد ذلك هو خواصها الفيزيائية والكيمائية المتفردة .ومن بين األشكال المتعددة لمنتجات
المستهلك النهائي وجدت مركبات الفضة النانوية اهتماما كبيرا في العديد من االستخدامات
التجارية الممكنة .ونسبة للمزايا المتفردة التي تتمتع بها مركبات الفضة النانوية (خاصة عملها
كمضادات للجراثيم) تضاعف انتاج المنتجات التي يعتمد انتاجها على هذه المركبات .وهذا مما
شأنه أن يزيد من احتمال تعرض البشر في المجاالت المهنية واالستهالكية لتلك المركبات .ولقي
تعرض البشر لهذه المركبات النانوية عن طريق التنفس اهتماما كبيرا نسبة لما قد تحدثه من
أضرار بالرئتين ،ولقدرتها على عبور الحاجز بين الشعيرات الدموية واألسناخ ،وأن تتوزع إلى
أعضاء في الجسم بعيدة عن الرئتين .غير أن اآللية التي يحدث بها التعرض التنفسي لمركبات
الفضة النانوية آثارا فيزيولوجية – مرضية على الجهاز القلبي الوعائي ،واألعضاء البعيدة
األخرى (مثل الكبد والكلى والطحال والدماغ) ليست مفهومة تماما .لذا فقد كان الهدف الرئيس من
هذه األطروحة هو تقييم تأثيرات وضع طبقة خارجية من مادة بولي فينيل بايرولدون والسترات
على آثار التعرض لمركبات الفضة النانوية ( (10 nmعن طريق التنفس في الجهاز القلبي
الوعائي واألعضاء األخرى (مثل الكبد والكلى والطحال والدماغ) في الفئران .وكان الهدف من
الدراسة أيضا دراسة تأثير التعرض لتلك المركبات ليوم واحد أو سبعة أيام ،ودراسة تأثير
الجرعات المعطاة ( .)0.05, 0.5 and 5 mg/kgوبما أن بإمكان مركبات الفضة النانوية أن
تزف  /تنقل من المسالك الهوائية إلى مجرى الدم ،فإن بإمكانها نتيجة لذلك أن تتفاعل مع خاليا
الدم (مثل كريات الدم الحمراء) .إال أن اآلثار الفيزيولوجية – المرضية التي تحدثها تلك المركبات
على كريات الدم الحمراء ،وآلية عملها المحتملة لم تدرس بعد دراسةً وافية .لذا فقد قمنا بعمل
دراسة مختبرية خارج الجسم الدراسة لتقييم آثار وضع طبقة خارجية من مادة بولي فينيل
بايرولدون والسترات ( )10 nmفي جرعات ثالث ( )2.5, 10 and 40 µg/mlعلى كريات
الدم الحمراء المعزولة من فئران .أما في التجارب داخل الجسم فقد قمنا بإعطاء المادة عن طريق
التستيل الرغامي ،وقمنا بعد ذلك بدراسة مختلف النقاط النهائية القلبية والجهازية ،والتي شملت
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الخثار وااللتهاب واالجهاد التأكسدي ،وضرر الحامض النووي عقب يوم أو سبعة أيام من
التعرض .وأحدث ترسب مركبات الفضة النانوية في الرئة آثارا قلبية وعائية معتمدة على الجرعة
ي ال ُمبَ ْر َمج.
شملت الخثار وااللتهاب واالجهاد التأكسدي وضرر الحامض النووي وال َم ْوتُ ال َخلَ ِو ُّ
وبقيت تلك اآلثار حتى بعد سبعة أيام من التعرض للمركبات .ودرسنا أيضا توزيع هذه المركبات
في أعضاء غير الرئة ،فوجدناها في الطحال والكبد ،وإلى حد أقل في الكلى والقلب والدماغ.
ووجدنا أيضا أن مركبات الفضة النانوية المغطاة بمادتي بولي فينيل بايرولدون والسترات قد
أحدثت التهابا واجهادا تأكسديا في تلك األعضاء المذكورة كما وضح من االرتفاع المعتد به
إحصائيا في عامل نخر الورم الفا ،وانترليوكين –  ،6وغلوتاثيون ،ومضادات األكسدة الكلية،
واكسيد النتريك ،ومادة  – 8ايسو بروستين ،إضافة للضرر في الحامض النووي واحداث ال َم ْوتُ
ي ال ُم َب ْر َمج في الرئة والقلب والكبد والدماغ ،المقاس بطريقتي  – 8هيدروكسي – – 2
ال َخلَ ِو ُّ
ديوكسي قوانيزين و  .TUNELووجدنا في الدراسات المختبرية (خارج الجسم) أن تغطية
مركبات الفضة النانوية بالمادتين المذكورتين سببت انحالال في الدم وإجهادا تأكسديا ،وزيادة في
تركيز ايونات الكالسيوم في العصارة الخلوية ،وفي االتحاد مع مادة انكسين ،وفي نشاط بروتين
كالبين .وكانت كل تلك األفعال معتدة إحصائيا ومعتمدة على الجرعة.
خلصت الدراسة إلى أن ترسب مركبات الفضة النانوية في الرئة قد أفضى إلى التهاب وإجهاد
تأكسدي .وخلصت أيضا إلى أن هذه المركبات تنتقل من الرئة وتتوزع إلى أعضاء بعيدة عنها
شملت القلب والكبد والكلى والطحال والدماغ ،وتسببت في ارتفاع مؤشرات االجهاد التأكسدي،
ي ال ُم َب ْر َمج.
والسيتوكينات االلتهابية ،وكذلك في ضرر الحامض النووي واحداث ال َم ْوتُ ال َخلَ ِو ُّ
وجد أيضا أن مركبات الفضة النانوية تسبب أفعاال تقود إلى زيادة التخثر ،وتغير من مؤشرات
التجلط .وأثبتت النتائج التي تحصلنا عليها من تجارب مختبرية (خارج الجسم) أن مركبات الفضة
ي
النانوية مع مادة بولي فينيل بايرولدون والسترات تسبب انحالال في الدم وتحدث ال َم ْوتُ ال َخلَ ِو ُّ
ال ُمبَ ْر َمج في الكريات الحمراء .وعلى وجه اإلجمال ،النتائج المتحصل عليها من داخل وخارج
الجسم ال تؤكد فقط اآلليات المعروفة عن طريقة إحداث ضرر الحامض النووي الذي تسببه المواد
ي ال ُمبَ ْر َمج ،بل
المحدثة للتأكسد ،والتي تفضي إلى اختالل وظائف الخاليا واحداث ال َم ْوتُ ال َخلَ ِو ُّ
تعرض آلية مبتكرة لآلثار المرضية – الفيزيولوجية الناتجة عن التعرض لمركبات الفضة النانوية
عن طريق الرئة ،وعن توزيعها في األنسجة األخرى.
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مفاهيم البحث الرئيسية :مركبات الفضة النانوية ،اإلجهاد التأكسدي ،االلتهاب ،موت الخاليا
المبرمج  ،ضرر الحمض النووي.
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Chapter 1: Introduction
1.1 Nanotechnology
The concept of the novel nanoscale technology was introduced in 1959 in the
lecture of physicist Richard Feynman entitled “There is plenty of room at the bottom”;
which discussed the importance of manipulating and controlling things at the atomic
scale [1]. The term nanotechnology was first introduced by Professor Norio Taniguchi
in 1974, and the American engineer Kim Eric Drexler, popularized the concept of
molecular nanotechnology by using it in his 1986 book Engines of Creation; The
Coming Era of Nanotechnology [1]. However, it was only after 1981 following
invention of the scanning tunneling microscope and atomic force microscope that the
growth of nanotechnology spurred [1]. The emerging and exponential nanotechnology
involves manipulation, design and precision placement of atoms and molecules at the
nanoscale level [1]. Over the past two decades, nanotechnology has witnessed
breakthroughs in the fields of medicine, environment, therapeutics, drug development
and biotechnology. This is due to unique properties of nanomaterials (NMs), such as
small size, large surface area to volume ratio, high reactivity, high carrier capacity and
easy variation of surface properties, which makes them desirable for commercial and
medical applications [2]. Considering the broad spectrum use of NMs, nanotechnology
has a great potential in improving treatment of various disorders and in vitro
diagnostics. These wide applications raise questions as to potential environmental and
health effects that might result from occupational exposures during manufacture and
use of NMs at the consumer end [3]. NMs can enter the bloodstream via inhalation or
ingestion and are able to cross biological membranes and access cells, tissues and
organs that larger-sized particles normally cannot [3]. This may lead to both
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genotoxicity and biochemical toxicity [4]. Toxic effect of NMs on humans has recently
gained much attention in the health industry [5, 6]. As NMs are involved for medicine,
diagnostic and other technological advances, an understanding of the toxicology of
these new materials is therefore much needed.
Some of the most commonly applied NMs include fullerenes, carbon
nanotubes (CNTs), silver nanoparticles (AgNPs), gold nanoparticles (AuNPs),
titanium oxide nanoparticles (TiO2), zinc oxide nanoparticles, iron oxide (FeO) and
silica nanoparticles (SiNP) [7]. Among these NMs, AgNPs have gained strong
popularity in research over the past few decades [7]. Initial investigations on AgNPs
were more focused on synthesizing and characterizing them using chemical
approaches. However, current works are concentrated more on their biological effects
and applications for several purposes [8]. AgNPs are also known to have unique
properties in terms of toxicity, surface plasmon resonance, and electrical resistance
[8]. Based on these, intensive works have been conducted to investigate their
properties and potential applications for several purposes such as antimicrobial agents
in wound dressings, water disinfectants, electronic devices and anticancer agents [8,
9].
1.1.1 Engineered nanomaterials
A major element of nanotechnology comprises of the engineered nanomaterials
(ENMs). According to European commission NMs means “A natural, incidental or
manufactured material containing particles, in an unbound state or as an aggregate
or as an agglomerate and where, for 50% or more of the particles in the number size
distribution, one or more external dimensions is in the size range 1 nm - 100 nm” [10].
The International Organization for Standardization (ISO) defines NMs “as a material
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having any external dimension in the nanoscale or having internal structure or surface
structure in the nanoscale”. ISO classifies NMs in two main categories: Nano-objects
and nanostructured materials. Nanoparticles (NPs) are nano-objects with all external
dimensions at the nanoscale where lengths of the longest and shortest axes of the nanoobject do not differ significantly.
NMs are comprised of 3 layers; a) the outer surface layer which may be
modified by variety of small molecule, metal ions, surfactant and polymers, b) the
intermediate shell layer and c) the core, which is the central portion and usually refers
to the NPs itself [11]. Based on their origin, NMs can be grouped in 3 main categories,
i.e naturally produced, incidental and engineered nanoparticles (ENPs). Naturally
produced NMs can be found in the bodies of organisms, insects, plants, animals and
human bodies [4]. In fact, nanostructures contribute to the basic foundation for all life
forms on Earth as evident by nanometer sized genetic materials (DNA or RNA),
proteins, antibodies, enzymes and other secretions that are highly beneficial for the
proper functioning of human body. Incidental NMs are produced incidentally as a
byproduct of industrial processes such as NPs produced from vehicle engine exhaust,
welding fumes, combustion processes and even some natural process such as forest
fires, volcanic eruptions, dust storms and photochemical reactions [4]. Incidental and
naturally occurring NMs are continuously being formed within and distributed
throughout soil, water and air. ENPs are type of synthetic NPs, deliberately developed
by humans to be used in applications, for e.g., carbon black, fumed silica, titanium
dioxide (TiO2), iron oxide (FeO), quantum dots (QDs), fullerenes, carbon nanotubes
(CNTs) and dendrimers [12]. One of the main differences between incidental and
ENPs is that the morphology (i.e. size, shape and composition) of engineered ENPs
can usually be better controlled as compared to incidental NMs.
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NMs can also be classified in the basis of their overalls shape; 0 dimensional
(D), 1 dimensional (1D), 2 dimensional (2D) and 3 dimensional (3D) NMs [13].
Electrons in D are confined in all directions and NPs are isolated from each other [13].
1D NPs include nanowire, nanorods and are often used as circuitry of computer chips
and for anti-reflective properties and hard coatings on eyeglasses [13]. 2D NPs include
graphene and are often used as nanocoating or nanopore filters used for small particle
separation and filtration [13]. 3D nanomaterials have all their dimensions at
macroscale, hence usually not covered under nanoparticles [13]. NPs can also be
categorized depending on their physical and chemical properties. Some of the wellknown classes include carbon based, metallic, ceramic, semiconductors, polymeric
and lipid-based NPs [2].
ENPs can be prepared from a variety of materials such as proteins,
polysaccharides and synthetic polymers and their preparation method usually includes
dispersion of preformed polymers, ionic gelation or coacervation of hydrophilic
polymers and polymerization of monomers [14]. Two broad approaches are applied
for synthesis of NPs, top down syntheses and bottom up syntheses. In top down
syntheses, larger molecules are decomposed into smaller units which are converted
into NPs [2]. This destructive method uses microfabrication technique where
extremely controlled tools cut, mill and shape materials in desired shape and size [15].
The bottom up syntheses are employed in reverse. uses smaller molecular components
to form complex assemblies, and therefore, called as building approach [2]. Examples
of this case are sedimentation and reduction techniques [2].
Nanomaterials have unique properties relative to bulk counterpart which
impart them beneficial characteristics; ironically, they may also bestow them with
unique mechanisms of toxicity. In general, toxicity has been thought to originate from
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nanomaterials’ size and surface area, composition, shapes, and so on. For instance, the
main reasons why materials built of ENPs have different electrical, magnetic, chemical
and mechanical properties from their bulk counterparts are that in this size-range
quantum effects start to predominate, and the surface-area-to-volume ratio becomes
very large [1]. The surface to volume of most materials increases gradually as their
particles become smaller, which results in increased adsorption of the surrounding
atoms and changes their properties and behavior. Once particles become small enough,
they start to obey the quantum mechanical laws. The nanoscale size also influences
their optical properties, reactivity and toughness and it is the optical property, which
imparts different colors to various NPs, due to absorption in the visible region.
Moreover, materials reduced to the nanoscale can suddenly show very different
properties, compared to what they exhibit on the macro-scale, which again enables
unique applications. For example, opaque substances become transparent (copper);
stable materials become combustible (aluminum); inert materials become catalysts
(platinum); insulators become conductors (silicon); solids turn into liquids at room
temperature (gold) [3].
The unique characteristics of NPs make them suitable candidates for various
domestic, commercial and environmental applications. A list of common NPs and their
major applications is presented in Table 1. NPs enabled products range from cosmetics
to sporting goods and serve a variety of functions: everything from acting as UVblocking agents to making plastics that are extremely light, but stronger than steel.
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Table 1: Common nanoparticles and their major applications.
Nanoparticles
Ag

Application
Medicine (wound dressings, drug delivery, biosensors and

References
[16]

medical diagnostics, orthopedics), food and textile
industries, and water disinfection systems
Fe/Fe2O3

Environmental remediation: degradation of organic dyes,

[17]

chlorinated organic pollutants and heavy metals removal,
MRI, magnetic data storage, Contrast agent for targeted
tumor imaging, magnetic sensing probes for in vitro
diagnostics, drug and gene carriers, therapeutic agents in
chemotherapy
CNT

Consumer electronics

[18]

Air and water filtration, thermal materials, catalysts
support
TiO2

Paints and coating for antimicrobial properties

[19]

Degrading organic contaminants and germs
Cosmetics as UV absorber
Fullereness

Drug delivery, anti-ageing and anti-damaging agent in

[20]

cosmetics
Anti-viral agents
Au

Medical diagnostics, sensing, targeted drug delivery,

[21]

imaging, photothermal and photodynamic therapy

The rapid expansion and application of nanotechnology naturally leads to
increased potential of exposure of ENMs both at occupational and consumer end.
Production, use, disposal, and waste treatment of products containing nanoproducts
are the prime reasons for the environmental release of nanoparticulate in the original
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or modified forms. These particles released in human environment can be inhaled and
most exposure to airborne NMs occurs in the work place [22]. Workers may be
exposed to nano-scale materials while manufacturing these materials, formulating
them into products, transporting them or handling them in the storage facilities.
Additionally, as nanotechnology is available on the market for great variety of
applications, widespread consumer exposure via direct contact with ENP-containing
product is likely. The small size of NPs facilitates translocation of active chemical
species from natural barriers such as the skin, lung, body tissues and organs [23]. For
example, NPs that are inhaled can effortlessly reach the bloodstream and interact with
blood cells and other sites in the human body including the liver, heart or brain [23].
Reactive oxygen species generation, protein denaturation, mitochondrial disconcertion
and perturbation of phagocytic functions are acute toxic effects of NPs [4]. On the
other hand, uptake by the reticuloendothelial system, nucleus, neuronal tissue and the
generation of neoantigens that causes possible organ enlargement and dysfunction are
common chronic toxic effects of NPs [4]. Other than penetration, electrostatic charges,
van der Waals forces, interfacial tension effects and steric interaction of NPs bind with
cellular components and cause cell death [4]. A wide variety of NPs can create reactive
oxygen species and cause cellular damage via lipid peroxidation, protein alteration,
DNA disruption, signaling function interference and gene transcription modulation
[4]. The fate of oxidative products relies on the chemistry, shape, size and location of
the NPs. NPs can relocate or distribute to various cellular sites such as the cytoplasm,
components of cytoplasm and nucleus. NPs can harm cell organelles or DNA and
cause cell mortality with their cellular localization effect [15].
Though NPs are useful for many applications, but still there are some health
hazard concerns due to their uncontrollable use and discharge to natural environment,
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Hence, nanotoxicology warrants intensive research studies in order to consider the use
of NPs more convenient and environment friendly.
1.2 Silver nanoparticles
Of all the ENMs developed and characterized thus far, AgNPs assume a
significant position owing to their potential uses in commercial applications [24, 25].
Silver, symbolized as Ag, is lustrous, soft, ductile and malleable metal, having the
highest electrical conductivity of all metals and is widely used in fabricating printed
electrical circuits and as a vapour-deposited coating for electronic conductors in
electrical appliances [26]. This precious metal is chemically inactive, stable in water
and does not oxidize in air, hence, used in manufacturing of coins, ornaments and
jewelry [26]. Silver can be obtained from pure deposits as well as from silver ores such
as horn silver and argentite. Most silver is derived as a by-product along with deposits
of ores containing gold, copper, or lead [26]. It is estimated that nearly 320 tons of Ag
NPs are manufactured every year and used in nanomedical imaging, biosensing and
food products [27, 28]. AgNPs exhibit special properties relative to their bulk
components due to their unique physicochemical properties including small size,
greater surface area, surface chemistry, shape, particle morphology, particle
composition, coating/capping, agglomeration, rate of particle dissolution, particle
reactivity in solution, efficiency of ion release, and the type of reducing agents used
for the synthesis of AgNPs [9, 16]. In addition, AgNPs are also well known for their
antimicrobial, optical, electrical, and catalytic properties [8]. Owing to their unique
properties, AgNPs have been extensively used in house-hold utensils, food storage,
health care industry, environmental, and biomedical applications such as wound
dressings, surgical instruments and disinfectants [16]. Further, due to their optical
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activities these NPs have been used in catalysis, electronics and biosensors [16].
1.2.1 AgNPs synthesis and characterization
Numerous methods have been adopted for synthesis of AgNPs in order to meet
the increasing requirements. The conventional physical method of synthesis includes
spark discharge and pyrolysis [29, 30]. Chemical method which can be top down or
bottom up approach involves three main components; metal precursors, reducing
agents, stabilizing/capping agents [9]. The common approach usually is chemical
reduction by organic or inorganic reducing agents, such as, sodium citrate, ascorbate,
sodium borohydride, elemental hydrogen, polyol process, Tollens reagent, N, Ndimethylformamide, and polyethylene glycol-block copolymer [9]. Other procedures
includes cryochemical synthesis, laser ablation, lithography, electrochemical
reduction, laser irradiation, sono-decomposition and thermal decomposition [9]. The
major advantage of chemical method is high yield unlike the physical method which
has low yield [31]. However, contrary to physical method, chemical method is
extremely expensive, toxic and hazardous [31]. In order to overcome the later
limitations, biologically mediated synthesis of NPs have emerged as better options.
This simple, cost effective and environment friendly approach uses biological systems
including bacteria, fungi, plant extracts, and small biomolecules like vitamins, amino
acids and enzymes for the synthesis of AgNPs [32]. The green approach is widely
accepted due to availability of a vast array of biological resources, decreased time
requirement, high density, stability, and the ready solubility of prepared NPs in water
[32].
Characterization of AgNPs is a very crucial step to evaluate the functional
effect of synthesized particle [9]. It has been documented in various studies that
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biological activity of AgNPs depends on morphology, structure, size, shape, charge
and coating/capping, chemical composition, redox potential, particle dissolution, ion
release and degree of aggregation [28, 33-36]. Like all other NPs, these parameters can
be determined using various analytical techniques, such as dynamic light scattering
(DLS), zeta potential, advanced microscopic techniques as atomic force microscopy,
scanning electron microscopy (SEM) and transmission electron microscopy (TEM),
UV-vis spectroscopy, X-ray diffractometry (XRD), fourier transform infrared
spectroscopy (FTIR), and X-ray photoelectron spectroscopy (XPS) [9, 37]. To capture
the concept of importance of AgNPs characterization, it must be noted that from
toxicological perspective studies using similar AgNPs provided by the same
manufacturer demonstrated different results. For example, a repeated exposure study
by Vandebriel RJ et al. [38] in rats showed that AgNPs are cytotoxic to various cells.
Contradicting to that, Boudreau M.D et al. [39] using similar particles, showed dose
dependent accumulation of AgNPs in various tissues of rats, without causing
significant cytotoxicity. Moreover, some published nanotoxicity studies reported
characteristics of the particles, using only manufacturer’s data without investigators
confirming the characteristics or using single analytical tool which provides limited
information about the particle-type being studied [38, 40-42]. This brings in the
importance of adequate physicochemical characterization of AgNPs prior to
undertaking toxicity assessments studies. In addition, a standardized measurement
approach like the application of validated methods and use of reference materials
specific to AgNPs, needs to be more developed in order to assure the comparability of
results among toxicity studies using similar AgNPs.
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1.2.2 AgNPs physicochemical properties
Size is an important property that influence the NPs uptake and effect. In this
regard, a review study reported that the common sizes of AgNPs used in general
applications range from 1 to 10 nm [43]. The reason behind this is smaller particles
displayed better antimicrobial and cytotoxic activity as demonstrated in various studies
[41, 44, 45]. Furthermore, as the particle size gets smaller, the specific surface area
increases and hence greater proportion of its atoms are displayed on the surface [3]
This implies that for the same mass of a NP, biological interactions and toxicity are
more dependent on particle number and surface area than by particle mass. The
properties of AgNPs can be further enhanced by functionalization of the NPs by using
various coatings which in turn influences NPs’ surface charge, solubility, and/or
hydrophobicity. There are considerable literatures that suggests fate and toxicity of
AgNPs are determined by the types of coating [46, 47]. Various types of surface
coatings applied to AgNPs, particularly to improve their biocompatibility and stability
against agglomeration are trisodium citrate (CT-AgNP), sodium bis(2-ethylhexyl)
sulfosuccinate, cetyltrimethylammonium bromide, polyvinylpyrrolidone (PVPAgNP), poly(L-lysine), bovine serum albumin, Brij 35 and Tween 20 [48]. Among the
latter, CT- and PVP- coating are the most commonly used as stabilizing agent [43].
Furthermore, the coating also modifies their charge which again influence the toxic
effect in cells. For example, positively charged NPs are considered more suitable drug
delivery tool for anticancer drug as they can stay for a long time in the blood stream
compared to negatively charged particles [9]. Shape-dependent effects were also
reported in studies using varying size AgNPs. For instance, silver nanocubes showed
greater antibacterial effect against E.coli compared to spheres and wires in a study
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using 55 nm AgNPs [49]. Pal. S et al. [50] also successfully demonstrated a shape
dependent interaction with Escherichia coli where truncated triangular had stronger
biocidal action than spherical and rod shaped AgNPs. Contrarily, Actis et al. [51]
reported no biocidal effect on Staphylococcus aureus using spherical, triangular and
cuboid AgNPs. Cellular uptake and biological responses are also defined by the
agglomeration state of NPs and there are sufficient evidences that interaction of the
AgNPs with biological media and biomolecules can lead to particle agglomeration as
well as aggregation [52, 53]. Though easy penetration of agglomerated AgNPs in
mesenchymal stems cells and nuclei were reported in several studies, reduced
cytotoxicity were also evident with agglomerated particles compared to free AgNPs
[52, 54]. A good amount of research has also been conducted on various types of
surface corona resulting from interfacial interactions between AgNPs and biological
fluid [55]. This included studies involving both single and complex molecule protein
coronas like bovine and human serum albumin, tubulin, ubiquitin, fetal bovine serum
etc [56]. The formation of corona depending on composition have shown to interfere
with the AgNPs dissolution to Ag ions and thus toxicity [56]. Researchers also
successfully established the importance of various AgNPs formulation during
synthesis with respect to biomedical applications [57]. For example, loading of AgNPs
inside multiwalled carbon nanotubes demonstrated improved targeting of AgNPs to
sperm cells and hence potential for development as diagnostic tool for the infertility
management [58]. Similarly, Bilal et al. [59] synthesized AgNPs loaded chitosanalginate construct which interestingly showed excellent biocompatibility to normal
cell line (L929) and cytotoxicity to cancer cells (HeLa cells). Azizi et al. [60]
formulated albumin coated AgNPs with the aim of developing new anticancer agents
and showed that the latter was taken specifically by tumor cells and induced apoptosis.
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1.2.3 AgNPs application and mechanism of action
Among various metal salts and NMs that are known to be effective in inhibiting
the growth of many bacteria, AgNPs are accounted for their strong inhibitory and
bactericidal effects [61, 62]. The use of AgNPs as well as Ag salts in catheters, cuts,
burns and wounds to protect them against infection have been well established [6366]. However, the exact mechanism underlying the antimicrobial effects of AgNPs is
still unresolved, though literature suggests that these particles can interact with the
membranes of bacteria [67, 68]. A potential pathway proposed is AgNPs, on
interaction with bacteria, induce reactive oxygen species and free radicals damaging
the intracellular organelles and modulating the intracellular signaling pathways
towards apoptosis [69]. Another widely accepted mechanism of bacterial cytotoxicity
is adhesion of AgNPs to bacterial wall, followed by infiltration of the particles,
bacterial cell membrane damage leading to leakage of cellular contents and death [67,
70]. In this context, the antimicrobial activity assessment of small sized AgNPs (12
nm) by Das et al. [71] demonstrated these NPs to be excellent inhibitors against both
Gram positive and Gram negative bacteria including, Staphylococcus Basillus,
Staphylococcus Aureus, and Pseudomonas Aeruginosa. This indicate that both
membrane thickness and surface charge facilitates particle attachment onto the cell
membrane [72]. Finally, large surface area of AgNPs releasing silver ions (Ag+) is
another crucial factor contributing to the cytotoxic activity. As it is well established,
smaller AgNPs have a faster rate of Ag+ dissolution in the surrounding
microenvironment due to their larger surface area to volume ratio, and hence results in
increased bioavailability, enhanced distribution, and toxicity of Ag compared with
larger ones [73, 74]. Furthermore, Ag+ ions release rate is dependent on number of
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factors including size, shape, concentration, capping agent and colloidal state of NPs
[75, 76]. In particular, the rate of Ag+ ion release was shown to be associated with the
presence of chlorine, thiols, sulfur, and oxygen [77]. Released Ag+ ions are suggested
to interact with respiratory chain proteins on the membrane, interrupt intracellular
O2 reduction, and induce ROS production causing cellular oxidative stress in microbes
and death [78] AgNPs are also familiar for their antifungal, antiviral and antiinflammatory activity [76]. Several studies reported potent anti-fungal activity of
AgNPs against several phytopathogenic fungi (e.g. Alternaria alternate, Sclerotinia
sclerotiorum, Macrophomina

phaseolina, Rhizoctonia

solani, Botrytis

cinereal

and Curvularia lunata) as well as human pathogenic fungi (e.g. Candida and
Trichoderma sp) [79, 80]. Likewise, AgNPs have demonstrated efficient inhibitory
activities against several viruses including human immunodeficiency virus, hepatitis
B virus, herpes simplex virus, human parainfluenza virus, peste des petits ruminants
virus and bean yellow mosaic virus, a plant pathogenic virus [81-85]. Inflammation is
an early immunological response against foreign particles by tissue and interestingly,
AgNPs have been recently recognized to play important role as anti-inflammatory
agents. Studies evaluating the anti-inflammatory effect of AgNPs showed significant
reduction in wound inflammation, modulation of fibrogenic cytokines, down
regulation of pro-inflammatory cytokines and apoptosis in inflammatory cells [65, 86,
87].
1.2.4 Routes of exposure and biodistribution
The major routes of entry of NPs are ingestion, inhalation, dermal contact and,
directly in systemic circulation via intraperitoneal (i.p.) or intravenous (i.v.) injection
[22]. The various mode of exposure to AgNPs, their biodistribution and mechanisms

15
underlying the effects is illustrated in Figure 1. As AgNPs are extensively used in
various household and biomedical products, the following section would discuss the
various potential routes of entry of these NPs.
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Figure 1: Schematic representation of biodistribution and toxicity of silver nanoparticles (AgNPs) following various routes of exposure. After their
exposure, AgNPs are able to induce inflammation and oxidative stress at the site of exposure. Moreover, they can cross various biological barriers
and enter the systemic circulation. Intravenously administered AgNPs are directly available in the circulation. Then onwards, AgNPs are distributed
to various organs and cause organ specific pathophysiological effects. It remains to establish whether the effects observed in the distant organs are
due to direct impact of the translocated AgNPs or ions and/or particle-induced inflammatory and oxidative stress response at the site of exposure.
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1.2.4.1 Respiratory exposure
The release of AgNPs in the environment during manufacture, washing or
disposal of products enables the NPs to enter the human respiratory system through
inhalation [88]. Exposure assessment in a NMs manufacturing facility, showed
significant release of AgNPs during processing as soon as the reactor, dryer and
grinder were opened, leading to a potential occupational exposure even for wet
production processes [89]. Similar studies evaluating workplace exposure and health
hazard have reported that concentrations of AgNPs in the processes of manufacturing
and integration of AgNPs into various consumer products can reach up to 1.35 μg/m3
[90, 91]. Several healthcare, hygiene and antibacterial spray products containing
AgNPs have now entered in our daily use. Nazarenko et al. [92] and Lorenz et al. [93]
reported that, use of nanotechnology based consumer sprays containing AgNPs, can
lead to the generation of nanosized aerosols and the release of NPs near the human
breathing zone. Furthermore, Ag-treated textiles can be a source of AgNPs in the
washing solution when laundering fabrics, regardless of either conventional Ag or
nano Ag treatment [94]. A recent study, evaluating the effluent from a commercially
available silver nanowashing machine showed that AgNPs

at an average

concentration of 11 µg/L was released in the environment [95]. AgNPs with maximum
concentration of 145 µg/L was also reported to be released from the outdoor paints
during the initial runoff events [96]. An occupational study in silver manufacturing
plant revealed that AgNPs in the air increases during production and peak area
concentration of more than 290 µg/m3 can be been detected [90]. The authors
suggested the possibility for workers to be exposed to airborne AgNPs at
concentrations ranging from 0.005 to 0.289 mg/m3. In spite of considerable studies
evaluating pulmonary exposure and toxicity, there is still a lack of long-term toxicity
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data, consumer exposure data, and human health effect of AgNPs information.
Nevertheless, an occupational exposure limit of 0.19 μg/m3 for AgNPs, have been
proposed recently based on a subchronic rat inhalation toxicity study and taking in
consideration the human equivalent concentration with kinetics [97]. Following
inhalation, the transport and deposition of NPs is not uniform and is influenced by
several factors including flow rate, structure of airway, pulmonary function, age and
most importantly, the particle size [88]. Particles smaller than 0.1 μm have been shown
to deposit in lungs and trachea-bronchial region [22, 98]. Consequently, due to deeper
particle deposition, the clearance mechanism takes longer leading to prolonged
particle-tissue interaction and resulting in more pathophysiological effect [22]. In
addition, translocation in blood capillaries is relatively easy for particles with a
diameter lower than 0.1 μm [22]. The alveolar-capillary barrier consists of a very thin
monolayer of epithelial cells, endothelial cells of the capillaries and basement
membrane between the two cells, and maintains the homeostasis of the lung [22]. NPs
penetration have been demonstrated following damage to the epithelial layer of the
alveolar capillary membrane [22, 99].
1.2.4.2 Oral exposure
In the food industry, AgNPs are used in packaging and storage in order to
increase the shelf life and quality of the food [100]. Moreover, urban and industrial
effluents enter the aquatic ecosystem and accumulate along the tropic chains [101].
Thus, AgNPs in dietary supplements, coated food containers, water contamination or
accumulation in food fish and other aquatic organisms provides the potential sources
of oral exposure [100]. Recent studies also demonstrated that AgNPs incorporated in
food packaging can migrate from packaging into food under several usage conditions
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[102, 103]. Inhalation exposure during manufacture also leads ultimately to oral
exposure since particles cleared via the mucociliary escalator are swallowed and
cleared through the GIT. It is estimated that the amount of daily consumption of silver
in humans by ingestion is around 20-80 µg [22]. After ingestion the GIT serves as a
mucosal barrier that selectively promotes the degradation and uptake of nutrients such
as carbohydrates, peptides, and fats. NPs can act on the mucus layer and translocate to
blood stream and consequently access each organ upon crossing the epithelium. It has
been reported that the uptake of NPs with a diameter lower than 100 nm occurs mainly
by endocytosis in epithelial cells [104]. Within the enterocytes, AgNPs can trigger
oxidative stress, DNA damage and inflammations [22].
1.2.4.3 Skin and parenteral exposure
Human exposure to AgNPs may also take place through the skin, the largest
organ of the body and first-line of defense between the external environment and
internal environment. The potential of solid NPs to penetrate the healthy as wells
breached human skin and to diffuse into underlying structures have been well
demonstrated [105, 106]. In this context, the use of AgNPs in cosmetics production
have been estimated to reach up to 20%. In addition to cosmetics, dermal contact to
wound dressings and antibacterial textiles have also shown large diffusion of AgNPs
[107]. In the laboratory set up, i.v., i.p., subcutaneous injection enables the AgNPs to
directly gain access into systemic circulation. Further, the development of AgNPs
based drugs or drug carrier would enable the entry of these particles directly in human
circulatory system.
Following exposure, the distribution and toxicity of AgNPs is further discussed
broadly under the in vivo toxicity section of this introduction. In general, an exposure
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and gender related difference, in target tissue AgNPs accumulation were evident in
previous researches [108-111]. Next to biodistribution, assessment of clearance
behavior of NPs is an important indicator of cumulative toxicity. In this context, there
are several studies that have investigated the post exposure clearance kinetics
following subacute inhalation, i.v, and oral exposure to various sizes of AgNPs and
Ag+ ions [111-114]. These studies revealed silver clearance from most organs post
recovery period which was 17-days to 4 months. However, tissues with biological
barriers like brain and testis exhibited persistence of silver in long term oral exposure
studies, suggesting difficulty of the silver to be cleared from these organs [113, 114].
Persistence of silver in these organs also enhances the chances of increased toxicity.
1.2.5 Pathophysiological effects of AgNPs
The immense growth in manufacture of AgNPs based products, owing to their
unique physicochemical and functional properties, and their wide application has
raised concern about their possible impact on the environment and subsequently
human health. Hence, despite the favorable properties of AgNPs the increasing
concern about the possible impact has directed researchers to focus on the in vitro and
in vivo toxicity induced by these particles.
1.2.5.1 In vitro effects
In vitro cytotoxicity studies often are used to characterize the biological
response to AgNPs and the results of these studies may be used to identify hazards
associated with exposure to AgNPs. Some important studies that have shown toxic
effect of AgNPs on different cell lines including, macrophages (RAW 264.7),
including bronchial epithelial cells (BEAS-2B), alveolar epithelial cells (A549),
hepatocytes (C3A, HepG2), colon cells (Caco2), skin keratinocytes (HaCaT), human
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epidermal keratinocytes (HEKs), erythrocytes, neuroblastoma cells, embryonic kidney
cells (HEK293T), porcine kidney cells (Pk 15), monocytic cells (THP-1) and stem
cells [55, 115-124], are discussed below.
Exposure of A549 cells to increasing concentrations of AgNPs for 24 hrs,
caused morphological changes including cell shrinkage, few cellular extensions and
restricted spreading pattern, and cell death in a dose-dependent manner [125]. In
another study using the same type of cell, treatment with 20 nm AgNPs induced DNA
damage and overexpression of metallothioneins at a concentration of 0.6 nM up to 48
hrs [126]. Size-dependent changes in cellular morphology was observed in rat alveolar
macrophage cell line incubated with hydrocarbon-coated AgNPs of different sizes (15,
30 and 55 nm) [127]. Gliga et al. [34] explored the mechanism of toxicity in BEAS2B cells exposed to CT- AgNPs of different particle sizes (10, 40 and 75 nm) as well
as to 10 nm PVP coated and 50 nm uncoated AgNPs. In the latter study, cytotoxicity
was evaluated using Almar Blue and lactate dehydrogenase (LDH) assay. The Almar
Blue assessed the cell viability and proliferation based on the reduction potential of
metabolically active cells. Their results showed cytotoxicity only of the 10 nm
particles independently of surface coating, and toxicity observed was associated with
the rate of intracellular Ag release, a ‘Trojan horse’ effect. Nguyen et al. [47] exposed
macrophage cell line to uncoated (20, 40, 60 and 80 nm) and PVP- AgNPs (10, 50,
and 75 nm) and found a cell shrinkage effect due to uncoated particles, whereas cell
elongation was evident after treatment with PVP-coated particles. Exposure of BEAS2B and RAW 264.7 cell lines to 20 and 110 nm PVP- and CT- Ag-AuNPs (AgNPs
with a gold core) showed that the 20 nm Ag-AuNPs induced significant reduction in
cell viability, in the dose range from 6.25-50 μg/mL for 24 hrs [128]. In addition,
significant reactive oxygen species (ROS) generation, intracellular calcium influx and
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decline in mitochondrial membrane potential were also demonstrated in 20 nm CTand PVP- AgNPs and 110 nm CT- AgNPs treated cells. Bastos V. et al. [129] also
evaluated the cytotoxicity of 30 nm CT- AgNPs on RAW 264.7 cells, using parameters
including viability, oxidative stress, and cytostaticity, at 24 and 48 hrs of exposure.
Their findings revealed decreased cell proliferation and viability at a concentration of
only 75 μg/mL, thereby suggesting low sensitivity of RAW 264.7 cells to lower doses
of AgNPs. Recently, Gliga et al. [123], using a combination of RNA sequence and
functional assays, showed that repeated, low dose (1 µg/ml), long term exposure (6
weeks)of BEAS-2B cells to 10 and 75 nm CT- AgNPs is profibrotic, indicated by
upregulation of TGFβ1 and induce epithelial-mesenchymal transition and cell
transformation. These evidences suggest that the observed cellular effects are dose,
size, coating and duration of exposure dependent.
Exposure of 20 nm AgNPs to C3A cells, at sublethal concentrations (1.95
µg/106 cells), revealed size dependent cytotoxicity indicated by elevated LDH,
increased release of inflammatory proteins (interleukin (IL) 8, tumor necrosis factor
(TNF) α, oxidative stress and decrease in albumin synthesis [130]. Cell viability were
also evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay, a colorimetric assay measuring cell metabolic activity based on
NADPH-dependent cellular oxidoreductase enzymes, in human hepatoblastoma
HepG2 and mice primary liver cells. Interestingly, AgNPs caused a concentration
dependent decrease of cell viability in both cell types [131]. A study by Xue et al.[132]
in HepG2 cells demonstrated that AgNPs are able to cause time (24 and 48 hrs) and
dose dependent (40, 80, 160 µg/ml) decrease in cell viability and induce cell-cycle
arrest in the G2/M phase, significantly increasing the apoptosis rate and ROS
generation. Similar study using PVP and CT- AgNPs at concentration of 1-100 mg/L
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also showed coating (CT causing more effect than PVP) and dose dependent reduction
in cell viability along with inhibition of albumin synthesis, decrease in alanine
transaminase activity and apoptosis in HepG2 cells indicating therapeutic potential of
the AgNPs against hepatic cancer [133]. Intestinal cells treated with Ag showed
induction of cytokine release and higher genotoxicity compared to other inorganic
metallic NPs (TiO2 and silicon dioxide) [134]. Böhmert et al. [135] analyzed the
toxicity of AgNPs with a primary size of 7.02 ± 0.68 nm in Caco-2 cells using NP
concentrations between 1 and 100 μg/ml. Partial aggregation between digested and
not-digested particles was observed by field fractionation (A4F) combined with DLS
and X-ray dispersion at small angles. The authors concluded that AgNPs entered the
GIT barrier without forming large aggregates in digestive fluids. These results
confirmed the importance of body fluids on NP behavior and toxicity.
Samberg et al. [136] assayed the potential cytotoxicity of AgNPs in HEKs
cells, following 24 hrs exposure and reported that unwashed and uncoated AgNPs
caused significant dose-dependent decrease of HEK cell viability and increase in
inflammatory cytokines, whereas washed and carbon-coated AgNPs did not induce
any effect. Moreover, in vitro percutaneous penetration of Ag study revealed the
accumulation of Ag and silver chloride aggregates of size less than 1 µm both in the
epidermis and dermis [137].
NPs readily enters systemic circulation and may interact with circulatory
components like blood cells, heart and blood vessel [138-140]. The potential impact
of AgNPs on hemolysis, platelet activity and coagulation associated with human
exposure have recently gained an interest. Studies using human erythrocytes have
investigated the effects of AgNPs on hemolysis, morphology and their uptake [139,
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141]. In our recent in vitro study, we assessed the effect of coating and dose of AgNPs
on oxidative damage and eryptosis on mouse erythrocytes [118]. Both PVP and CTAgNPs induced oxidative stress and increased cytosolic calcium, annexin V binding
and calpain activity. The latter data may explain the mechanism of hemolysis and
eryptosis induced by AgNPs. These NPs could also prevent platelet responses as
evidenced by the inhibitory effects of AgNPs of different sizes (13-15 nm, 30-35 nm
and 40-45 nm) on platelet aggregation [142]. Conversely, Bian et al. [143] recently
compared the AgNPs (<100 nm) with Ag macro particle (5-8 µm) and showed that the
former can promote phosphatidylserine (PS) exposure and microvesicles generation in
freshly isolated human erythrocytes, mainly through ROS generation and intracellular
calcium increase and hence suggesting that AgNPs may have prothrombotic risks by
promoting procoagulant activity of RBCs, more importantly at non-hemolytic
concentrations (≤ 100 μg/mL). These discrepancies in results, though not fully
understood, could be related to different cell type used in the studies. The various blood
biological effects of AgNPs, such as, hemolysis, interference on plasma coagulation,
enhancement of platelet aggregation and inhibition of lymphocyte proliferation, are
size, coating and concentration dependent [118, 144, 145]. Lin et al. [146] studied the
potential toxicity of AgNPs on cardiac electrophysiology. The particles caused
concentration dependent (10-9-10-6 g/ml) depolarization of resting membrane potential,
diminished action potential and subsequently led to loss of excitability in mice cardiac
papillary muscle cells in vitro. Milic M et al. [120] investigated the interaction of CTAgNPs (13-61 nm) with porcine kidney (Pk15) cells, and compared the effect of the
particles to ionic form. Both forms of silver, concentration (1-75 mg/l) dependently
decreased the viability of Pk15 cells after 24 hrs.
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Furthermore, AgNPs exhibited increased toxicity in stem cells which were
attributed to their properties such as size, concentration and coating. For eg., the
biocompatibility of 100 nm AgNPs was tested in human mesenchymal stem cells
(hMSCs) by Greulich C et al. [147] and there was a dose (0.5-50 µg/ml) dependent
effect on cytotoxicity exhibited by decreased cell proliferation and chemotaxis. In
addition, He W et al. [148], showed increased LDH release and ROS production and
reduction in both cell viability and mitochondrial membrane potential in hMSCs
exposed to 30 nm AgNPs. Murine spermatogonial stem cells showed less cell
viability, LDH leakage, and prolonged apoptosis after exposure to 15 nm AgNPs at
concentrations of 5, 10, 25, 50, and 100 μg/ml [149]. Similarly, neural stem cells
showed an increase in cell death, LDH leakage, induction of ROS, upregulation of proapoptotic Bax protein, and increased in apoptosis when exposed to various
concentrations (0.01-80 μg/mL) of PVP- Ag-NPs [150]. In the latter study, AgNPs
induced neurotoxicity was compared to Ag+ ions, and the authors demonstrated that
AgNPs caused cell apoptosis by inducing intracellular ROS generation coupled with
JNK phosphorylation while Ag ions caused cell necrosis via altering the cell
membrane integrity and binding with cellular thiol groups directly.
Results of the in vitro studies indicated that AgNPs are toxic to the mammalian
cells derived from skin, liver, lung, brain, vascular system and reproductive organs
[151]. Cytotoxicity of AgNPs depends on their size, shape, surface charge,
coating/capping agent, dosage, oxidation state, agglomeration and the type of
pathogens against which their toxicity is investigated [45, 115, 152, 153]. Despite the
number of studies, the toxicological mechanism is still unclear. Several studies
reported DNA damage and apoptosis induced by NPs. In this context, AgNPs were
shown to cause apoptosis in mouse embryonic stem cell [154]. A follow up by the
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same group also demonstrated involvement of AgNPs in activation of apoptotic
markers, caspase 3 and caspase 9, at concentration of 50 and 100 µg/mL [155]. DNA
damage at concentration of 0.1 µg/mL of AgNPs, was also reported in a study
investigating the chromosomal aberration in human mesenchymal cells [156].
Furthermore, the potential of AgNPs to induce genes associated with cell cycle
progression, cause chromosomal damage, cell cycle arrest and cell death in human
cells BEAS-2B, umblical vein endothelial cells and hepatocellular liver carcinoma
cells, at various concentrations were also reported [151]. In spite of these numerous
studies, a major limitation of the in vitro study in hazard identification with respect to
human health, is related to the doses used in the in vitro study which may not be
comparable to realistic exposure doses in human. Hence, this necessitates in vivo
toxicity research which are presented in the following section based on the potential
routes of exposure.
1.2.5.2 In vivo toxicity
In vivo biodistribution and toxicity studies in rats and mice have demonstrated
that AgNPs administered by inhalation, ingestion, i.v., or i.p. injection were
subsequently detected in blood and caused toxicity in several organs including lung,
liver, kidney, intestine and brain [157-159].
Inhalation is a proposed major route of exposure not only during manufacturing
of Ag containing materials but also during use of aerosolized products. Table 2 and 3
summarizes the important toxicity and biodistribution studies of AgNPs in rodents
following pulmonary exposure via inhalation and intratracheal (i.t.) instillation,
respectively. The data from these studies showed diverse outcomes related to
biodistribution and remote organ toxicity. Some studies showed no induction of
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adverse effects [160, 161], while other studies reported adverse effects varying from a
minimal inflammatory response to the presence of inflammatory lesions in the lungs
[110, 111, 162, 163]. For instance, a 28-days inhalation toxicity study on rats showed
no significant changes in the haematology and blood biochemistry in either the male
or female rats following 11-14 nm AgNPs at concentration of 1.73 x 104/cm3, 1.27 x
105/cm3 and 1.32 x 106 particles/cm3 [161]. Hyun et al. [164] also exposed rats to 1215 nm AgNPs for similar duration and doses and showed no remarkable
histopathological changes in the nasal cavity and lung, in the NPs exposed group
compared to the control group. Nevertheless, Lee et al. [165] found that a short term
(14 days) nose only exposure of mice to 20 nm AgNPs at concentration of
1.91 × 107 particles/cm3 led to alterations in brain gene expression. Sub-chronic (90
days) inhalation studies exhibited mild, dose-dependent pulmonary inflammation and
alterations in pulmonary function in rats exposed to 18 nm AgNPs [163]. In addition,
inhaled AgNPs may also enter the systemic circulation to become distributed to extrapulmonary organs such as the liver and brain as demonstrated in studies using ~15 nm
NPs at concentrations of 1-3 x 106 particles/cm3 [161, 166]. A 90 days inhalation study
by Sung et al. showed alterations in lung function and inflammatory responses in 18
nm AgNPs exposed rats [163]. Additionally, accumulation of Ag in lungs and liver
were more evident in rats after 90 days of inhalation [110]. Silver accumulation have
been also observed in brain, olfactory bulb, kidney and spleen [110, 167, 168].
Moreover, AgNPs (18-20 nm) have also been shown to reach and cross mouse placenta
in an inhalation study, where pregnant females were exposed to freshly produced
aerosols for either 1 or 4 hrs/day, during the first 15-days of gestation, at a particle
number concentration of 3.80 × 107 part/cm3 [169].
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Table 2: Toxicity and distribution of AgNPs following pulmonary exposure in
rodents via inhalation.
Size

Dose

Model

1114
nm

1.73 x
104/cm3 (low
dose), 1.27 x
105/cm3
(middle
dose), (1.32
x 106
particles/cm3
(high dose)

Sprague–
Dawley
rats

18
nm

0.7 × 106
particles/cm3
(low dose),
1.4 × 106
particles
/cm3 (middle
dose), and
2.9 × 106
particles/cm3
(high dose)
0.6 ×
106 particle/c
m3, 49
μg/m3(low
dose), 1.4 ×
106 particle/c
m3, 133
μg/m3
(middle
dose) and
3.0 ×
106 particle/c
m3, 515
μg/m3 (high
dose)
3.3 ± 0.5
mg/m3 or 31
µg/g lung

Sprague–
Dawley
rats

Inhalation
6h/day, 5
days/wk, for
90 days,
sacrificed 1day post last
exposure

Sprague–
Dawley
rats

Inhalation 6
h/day, 5
days/week, for
90 days,
sacrificed 1day post last
exposure

Male
C57Bl/6
mice

Inhalation
4h/day, 5 days
a week, for 10
days, sacrifice
at 1 hr and 21days post last
exposure

18
nm

10
nm

End-point
measurement
Inhalation 6
h/day, 5
days/wk, for 4
wk, sacrificed
1-day post last
exposure

Effect

Tissue
accumulation
Lu, Li, Br, Ob

References

N/A

[163]

Silver
accumulatio
n in kidney
was gender
dependent.
Dosedependent
increase of
bile duct
hyperplasia
in AgNP
exposed
liver

Lu, Li, Br, Ob,
Ki

[110]

Subacute
inhalation of
AgNPs
induced
minimal
pulmonary
toxicity

Lu

[162]

AgNPs
concentratio
n below the
American
Conference
of
Government
al Industrial
Hygienists
silver dust
limit (100
µg/m3) did
not produce
significant
toxic effects
Subchronic
exposure to
AgNPs
compromise
d the lung
function

[161]
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Table 2: Toxicity and distribution of AgNPs following pulmonary exposure
in rodents via inhalation (cont’d).
Size

Dose

Model

15
nm;
410
nm

179
μg/m3
and 167
μg/m3 or
7.9 × 106
particles/
mm3 and
118
particles/
mm3 for
15 and
410 nm,
respectiv
ely
8, 28 µg

Male
Fischer
rats

7.2 ± 0.8
mg/m3
and 5.3 ±
1.0
mg/m3 or
86 and
53 µg/rat
for C20
and C110
nm,
respectiv
ely
3.80 × 10
7 part.
/cm−3

15
nm

20
nm;
110
nm
(CT)

18-20
nm

End-point
measurement
Inhalation
6h/day, 4
consecutive
days, sacrifice
at 1- and 7days post
exposure

Effect

Tissue
accumulation
Lu, Li

References

BrownNorway
and
Sprague–
Dawley
rats

Inhalation 3h
for 1 day or 3h
for 4 days.
Sacrifice at 1
and 7-days
post last
exposure

AgNPs
induced an
acute
pulmonary
neutrophilic
inflammation
with the
production of
proinflammato
ry and proneutrophilic
cytokines

Lu

[170]

Male
Sprague–
Dawley
rats

Inhalation
6h/1day,
sacrifice at 1,
7, 21, 56 days
postexposure

Delayed peak
and shortlived
inflammatory
and cytotoxic
effects in
lungs with
greater
response due
to smaller
sized
nanoparticles
Increased
number of
resorbed
fetuses
associated
with reduced
oestrogen
levels, in the
4 hrs/day
exposed
mothers

N/A

[171]

Female
C57BL/6
mice

Inhalation for
1 hr/day or 4
hrs/day, for
first 15 days
of gestation,
sacrificed 4
hrs post last
exposure

Lu, Sp,
Li, Pl

[169]

Size
dependent
effect on
pulmonary
toxicity after
inhalation of
similar mass
concentration
of 15 and 410
nm AgNPs

[168]
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Table 3: Toxicity and distribution of AgNPs following pulmonary exposure in
rodents via intratracheal instillation.
Size

Dose

Model

End-point
measurement

Effect

Tissue
accumulation

References

20 nm;
110 nm
(PVP
& CT
coated)

0.5, 1
mg/kg

Male
Sprague–
Dawley
rats

Single i.t.
instillation,
sacrifice at 1,
7- and 21days post
exposure

Coating and
size dependent
AgNPs
retention in
lungs. PVP
coated AgNPs
had less
retention over
time and larger
particles were
more rapidly
cleared from
large airways
than smaller
particles

Lu

[172]

20 nm;
110 nm
(PVP
& CT
coated)

0.1, 0.5, 1
mg/kg

Male
Sprague–
Dawley
rats

Single i.t.
instillation,
sacrifice at 1,
7- and 21days post
exposure

Smaller sized
AgNPs
produced more
inflammatory
and cytotoxic
response.
Larger
particles
produce lasting
effects post 21
days
instillation

N/A

[173]

20 nm
(CT
capped)

1 mg/kg

Male
Sprague–
Dawley
rats

Single i.t.
instillation,
sacrifice at 1and 7-days
post exposure

AgNP resulted
in exacerbation
of cardiac
ischcemicreperfusion
injury

N/A

[174]

50 nm;
200 nm
(PVP
coated)

0.1875,
0.375,
0.75, 1.5,
3 mg/kg

Female
Wistar
rats

Single i.t.
instillation,
sacrifice at 3and 21-days
post exposure

Focal
accumulation
of Ag in
peripheral
organs along
with transient
inflammation
in lung

Li, Sp, Ki

[167]
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Table 3: Toxicity and distribution of AgNPs following pulmonary exposure
in rodents via intratracheal instillation (cont’d).
Size

Dose

Model

End-point
measurement

Effect

Tissue
accumulation

References

20 nm;
110
nm

1 mg/kg

Male
Sprague–
Dawley
rats

Single i.t.
instillation,
sacrifice at 1and 7-days
post exposure

Both sizes of
AgNP resulted
in exacerbation
cardiac I/R
injury 1 day
following
instillation
independent of
capping agent.
Persistence of
injury was
greater for
110 nm PVP
capped AgNP
following 7
days instillation

N/A

[175]

50 nm;
200
nm
(PVP,
CT
coated)

0.05, 0.5,
2.5 mg/kg

Female
Balb/C
mice

Single i.t.
instillation,
sacrifice 1day post
instillation

Size, dose and
coating
dependent proinflammatory
effects in
healthy and
sensitized lungs
following
pulmonary
exposure to
AgNPs

N/A

[107]

10 nm

0.05, 0.5,
5 mg/kg

Balb/C
mice

Single i.t.
instillation,
sacrifice at 1and 7-days
post exposure

Oxidative
stress, DNA
damage,
apoptosis in
heart.
Prothrombotic
events and
altered
coagulation
markers

N/A

[176]
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In several cases, a gender-dependent difference for AgNPs accumulation in
kidneys has been reported, with females exhibiting a higher concentration than males
[108, 163, 177]. One possible explanation for the sex differences in the distribution of
Ag may be hormonal regulation in the rat kidney [39]. Gender-dependent difference
was also reported in terms of persistence of pulmonary inflammation and decrease in
lung function in male rats following termination of exposure, while females showed
gradual improvement in lung inflammation following cessation of exposure [111].
However, the exact mechanism of sex related differences is still not clear.
The potential mechanisms of the cardiovascular effects of lung deposited
particles have been previously discussed by Nemmar et al. [178]. In this context,
Holland et al. [174] investigated the effect of 20 nm AgNPs on cardiovascular injury
and showed exacerbation of cardiac ischemic-reperfusion injury following single i.t.
instillation in rats. The authors further evaluated the impact of size (20 and 110 nm)
and coating (PVP and CT) of AgNPs and demonstrated that the acute effect was size
and coating independent, whereas the persistence of injury was greater for 110 nm
PVP- AgNPs [175]. A significant dose dependent effect of pulmonary exposed PVPand CT- AgNPs on cardiovascular homeostasis was also demonstrated in our recent
study [176]. The mechanism through which lung injury occurs and how the
physicochemical properties of inhaled AgNPs affect their interactions with the lung
have recently began to be investigated in vivo. [107, 168, 172, 173]. For instance, a
greater pulmonary inflammatory response was observed with instillation of 20 nm size
than a 110 nm size but with little influence imposed by CT or polyvinyl phosphatecapping in rats [179]. In addition, i.t. instillation of 5-150 µg AgNPs (50 nm) caused a
reversible inflammation while 300 µg led to DNA damage, accelerated cell
proliferation and progressively increased numbers of neutrophilic granulocytes in rat
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lungs [167]. Along with the in vitro studies, in vivo results suggest that size, coating
and dose affect pulmonary inflammation and cellular toxicity.
As mentioned above, besides respiratory exposure, consumer exposure to
AgNPs via ingestion can also occur due to incorporation of AgNP into products such
as food containers and dietary supplements. Table 4 summarizes the important toxicity
and biodistribution studies of AgNPs in rodents via oral exposure. The deposition of
orally exposed AgNPs in the GIT has been widely demonstrated in previous studies
[39, 180]. Jeong et al. [181] showed an increase of goblet cells in the intestine, together
with high mucus granule release in mice treated with AgNPs (60 nm), orally, at a
concentration of 30 mg/kg bw/day for 28-days. In addition, AgNPs (5-20 nm) orally
administrated for 21-days in mice (20 mg/kg of BW) disrupted epithelial cell microvilli
and intestinal glands [113]. Distribution of PVP- AgNPs (14 nm) to multiple organs
including intestine, liver, kidney, lung and brain following oral administration have
been reported [180]. Several other investigators also showed that oral exposure to
AgNPs may lead to liver, intestinal and neuronal damage [159, 182, 183]. Cases of
argyria, a condition characterized by irreversible gray or bluish gray pigmentation of
the skin, and irreversible neurologic toxicity and death have been reported upon longterm ingestion of colloidal silver [184]. Liver appears to be a major accumulation site
of circulatory AgNPs [157]. In fact, PVP- AgNPs (20-30 nm) have been shown to
increase oxidative stress, enhance autophagy and deplete insulin signaling pathway
following oral exposure for 90-days in the liver of male rats [159]. Changes in blood
parameters indicated by significant elevation of alanine transaminase (ALT) and
aspartate transaminase (AST) and hepatoxicity, shown by histological damages
(necrosis, hepatocytic inflammation, and resultant aggregation of lymphocytes in liver
tissue, were also observed in study evaluating toxic effect of 14-days orally exposed
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AgNPs (40 nm) at doses 20 and 50 ppm in Balb/C mice [185]. Moreover, Tiwari et al.
[186] determined the effect of 60-days AgNPs (10-40 nm) treatment on kidneys of
female Wistar rats at doses of 50 ppm and 200 ppm and demonstrated significant
mitochondrial damage, increased levels of serum creatinine and early toxicity marker
such as KIM-1, clusterin and osteopontin.
Table 4: Toxicity and biodistribution of AgNPs in rodents via oral exposure.
Size

Dose
mg/kg

Model

End-point
measurement

Effect

Tissue
accumulation

References

56
nm

30,
125,
500

F344
rats

Daily
exposure for
90 days,
sacrifice 24
hrs post last
exposure

Accumulation of silver
in kidneys was gender
dependent, with 2-fold
increase in female
kidneys. Liver is the
target of silver toxicity
for both male and
female rats.

Li, Ki, Br, Lu,
Bl

[109]

15
nm;
20
nm

90

Male
Sprague
Dawley
rats

Daily
exposure 28
days, sacrifice
24 hrs, 1
week, 8
weeks post
last exposure

Main target organ for
AgNPs and AgNO3
upon oral exposure are
the liver and spleen.
Silver was cleared
from all organs after 8
weeks post dosing
except brain and testis

Li, Sp, Te, Ki,
Br, Lu, Bl,
Blr, Ht

[113]

20
nm

820

Male
Sprague
Dawley
rats

Daily
exposure for
81 days,
sacrifice 24
hrs post last
exposure

AgNPs induces liver
and cardiac oxidative
stress and mild
inflammatory response
in liver

N/A

[187]

20
nm;
110
nm

10

Pregnant
Sprague
Dawley
rats

Single
exposure,
sacrificed at
24 hrs and 48
hrs post
exposure

Silver enters and
crosses placenta
regardless of route and
form of silver

Ce, LI, Pl, Ki,
Bl

[188]
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Table 4: Toxicity and biodistribution of AgNPs in rodents via oral exposure (cont’d).
Size

Dose
mg/kg

Model

End-point
measurement

Effect

Tissue
accumulation

References

20,
nm;
110
nm
(PVP
and
CT
coated)

0.1, 1,
10

Male
C57BL
/6NCrl
mice

3-days
exposure,
sacrifice at 1and 7-days
post exposure

Acutely ingested
AgNP,
irrespective of
size or coating,
are well-tolerated
in rodents even in
markedly high
doses and
associated with
predominant fecal
accumulation

Absence of
tissue
accumulation

[189]

10 nm;
75 nm;
110
nm

9, 18,
36

Spragu
e
Dawley
rats

Daily
exposure for
13-weeks.
Sacrifice 24hrs post last
exposure

Silver
accumulation in
tissues showed
size dependent
relationship
10>75>110.
Statistically
significant
difference in
distribution and
accumulation of
silver in male and
female rats. No
toxic effect on
blood,
reproductive and
genetic system
tested was
observed

Ki, Sp, Li, Ht,
Ut

[39]

91.71
± 1.6
nm

0.5

Male
Wistar
rats

Daily
exposure for
45-days,
sacrificed 24hrs post
exposure

AgNPs caused
significant
oxidative stress
compared to
TiO2NPs with
similar dose
concentration

Bl, Li, Ki

[190]

36
Table 4: Toxicity and biodistribution of AgNPs in rodents via oral exposure (cont’d).
Size

Dose
mg/kg

Model

End-point
measurement

Effect

Tissue
accumulation

References

20-30
nm
(PVP
coated)

50,
100,
200

Male
Sprague
Dawley
rats

Daily
exposure for
90-days,
sacrifice
24hrs post last
exposure

Though AgNPs
accumulated in
hepatic and ileum
cells, no harmful
effects in liver
and kidney, as
well as no
histopathological,
hematological
and biochemical
markers changes
was observed

Il, Li, Ki, Br,
Th, Spl

[191]

20-30
nm
(PVP
coated)

50,
100,
200

Male
Sprague
Dawley
rats

Daily
exposure for
90-days,
sacrifice 24hrs post last
exposure

High dose
showed an
increase of sperm
morphology
abnormalities

N/A

[192]

10 ± 4
nm (CT
capped)

0.2

Male
Wistar
rats

Daily
exposure for
14-days,
sacrifice 24
hrs post
exposure

Prolonged low
dose AgNPs
exposure induced
oxidative stress
in brain but not
in liver

N/A

[193]

20-30
nm
(PVP
coated)

50,
100,
200

Male
Sprague
Dawley
rats

Daily
exposure for
90-days,
sacrifice 24hrs post last
exposure

High dose of
AgNPs induced
hepatocellular
damage by
increased ROS
production,
enhanced
autophagy and
depleted insulin
signaling
pathway

N/A

[159]

The use of AgNPs in wound dressings and other applications designed to
regulate skin microbiome composition is an established strategy that has been shown
to inhibit a broad range of bacteria, including Pseudomonas aeruginosa, Escherichia
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coli and Staphylococcus aureus [61, 87]. Numerous reports indicate that AgNPs
promote wound healing by decreasing the inflammatory response [194, 195].
Nevertheless, an aspect that remains sparsely researched is the possibility of
sensitization of the skin by these NPs. It is well known that patients with wounds are
at particular risk of developing either an allergic or irritant contact dermatitis, and
silver compounds are widely used in wound care. Yet so far there has only been very
few confirmed case of contact dermatitis secondary to silver-containing wound
products like silver sulfadiazine and skin marker containing silver nitrate [196, 197]
Contrary, there are considerable evidence for significant transdermal penetration of
AgNPs into capillaries during use of surgical dressings, textiles or cosmetics [198,
199]. In order to elucidate the mechanism of cytotoxicity, Samberg et al. [136]
evaluated the potential ability of AgNPs to penetrate porcine skin and showed focal
inflammation and localization of AgNPs on the surface and in the upper stratum
corneum layers of porcine skin. Acute and sub-acute dermal studies conducted by
Korani et al. [6], suggested a correlation between dermal exposure, tissue
accumulations of AgNPs (100 nm) and dose-dependent histopathological
abnormalities in skin which was exhibited by reduced thickness of papillary layer and
epidermis. Compared to animals treated with single dose, animals that were subjected
to sub-chronic exposure, showed considerable accumulation of AgNPs in other like
liver and lung and dose dependent toxic response in several organs including spleen,
liver and skin [200].
Other potential route of AgNPs entry in case of biomedical applications
includes parenteral administration. A summary of important toxicity and
biodistribution studies of AgNP in rodents via exposure of i.v. injection is given in
Table 5. In a recent study, comparing the biodistribution and toxicological
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examinations after repeated i.v. administration of AgNPs and AuNPs in mice showed
more deposition of AgNPs in heart, lung and kidney than AuNPs [157]. Moreover, the
AgNPs induced adverse effects in a dose-dependent manner (the concentrations tested
were 4, 10, 20, 40 mg/kg) [157]. Another study, following subcutaneous
administration of AgNPs of different size, in rats, also revealed that the particles
translocated to the blood circulation and distributed throughout the main organs,
especially in the kidney, liver, spleen, brain and lung [138]. The results also suggested
the potential of AgNPs to cross blood-brain barrier and induce astrocyte swelling and
neuronal degeneration [138]. A few studies reported the transfer of AgNPs across
placenta in rats and mice [201, 202]. Following i.v. administration of 10 nm AgNPs,
at a dose of 66 µg Ag/mouse to pregnant animals on gestational days 7, 8 and 9, Ag
accumulation was revealed in all examined organs with highest being in maternal liver,
spleen and visceral yolk sac and the lowest concentrations in embryos [201]. Another
study comparing the administration methods (i.v. versus i.p.) showed similar
localization of Ag in liver and spleen for both methods [202]. However, Ag was
quickly excreted from the body with i.v. administration, compared with i.p.
administration. The latter study also showed that the AgNPs could cross the placental
barrier and the blood-testis resulting in accumulation in fetus and testis, respectively
[202].
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Table 5: Toxicity and biodistribution of AgNPs in rodens via intravenous injection.
Size

Dose

Model

End-point
measurement

Effect

Tissue
accumulation

References

1540
nm

4,10,20,40
mg/kg

Male
Wistar
rats

32 days i.v,
sacrifice 24hrs post last
i.v
administration

AgNPs in doses <
10 mg/kg is safe,
while > 20 mg/kg
is toxic

Li, Ki

[203]

21.8
nm

7.5, 30,
120
mg/kg

ICR mice

Single i.v,
parameters
measured at
1,7,14-days
post injection

Inflammatory
reactions in lung
and liver cells
were induced in
mice treated at the
high dose of
AgNPs. Gender
related
differences in
distribution and
elimantion of
AgNPs,
elimination in
female is longer
than the males.

Sp, Li, Lu, Ki

[204]

20
nm;
200
nm

5 mg/kg

Male
Wistar
rats

Single i.v,
sacrifice at 1,
7, 28-days
post i.v
administration

High tissue
concentration of
silver in tissues of
20 nm group as
compared to 200
nm groups

Li, Sp, Ki,
Lu, Br, Ur, Fe

[158]

7.2
±
3.3
nm

5,10,45
mg/kg

Male
SpragueDawley
rats

Daily tail vein
injection for 3
consecutive
days,
parameters
measured at 1
and 3rd day

Decrease in body
weight and
locomotor activity

N/A

[205]

3±
1.57
nm

11.4-13.3
mg/kg

Male
KunMing
mice

i.v. injection 2
times/week
for 4 weeks,
sacrifise at 1,
28, 56-days
post injection

AgNPs
preferentially
accumulated in all
major organs
compared to other
metallic NPs.

Li, Sp, Ki,
He, Lu, Te,
Fe, Bl, In, St,
Br, SV

[157]
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Table 5: Toxicity and biodistribution of AgNPs in rodens via intravenous injection
(cont’d).
Size

Dose

Model

End-point
measurement

Effect

Tissue
accumulation

References

20,
nm;
100
nm

0.0082,
0.0025,
0.074,
0.22,
0.67, 2,
6
mg/kg

Wistar
rats

28-days,
repeated i.v,
sacrifice at 24
hrs post last
injection

Immune system is
the most sensitive
parameter affected
by AgNPs;
reduced thymus
weight, increased
spleen weight and
spleen cell number,
strongly reduced
NK cell activity,
and reduced IFN-γ
production were
observed

N/A

[40]

20 nm

0.0082,
0.0025,
0.074,
0.22,
0.67, 2,
6
mg/kg

Male
Wistar
rats

28-days,
repeated i.v,
sacrifice at 24hrs post last
injection

AgNPs suppress
the functional
immune system

N/A

[38]

10 nm
(CT
coated)

1
mg/kg

CD1
mice

IV
administration,
once every 3
days, sacrifice
at 15, 60 120days post
initial
exposure

AgNPs induced
toxicity to male
reproduction,
altered Leydig cell
function, increased
testosterone level

Te

[206]

10 nm;
75 nm;
110
nm
(CT
coated)

0.1
mg/kg

Female
Balb/C
mice

Single dose
injection
sacrifice at 4
hrs, 1, 3 or 7days post
injection.
Multi dose: i.v
injection on
day 1, 4 and
10, sacrifice at
7-days post
last injection

Injection of a
single dose of
AgNPs induced a
less toxicity in
liver and lung
tissues than that
induced by multidose injections.
The toxic effect of
AgNPs was time
dependent

N/A

[207]
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Table 5: Toxicity and biodistribution of AgNPs in rodens via intravenous injection
(cont’d).
Size

Dose

Model

End-point
measurement

Effect

Tissue
accumulation

References

10 nm;
40 nm,
100
nm
(PVP
or CT
coated)

10
mg/kg

Male
CD-1
(ICR)
mice

Single i.v,
sacrifice at
24-hrs post
injection

10 nm AgNP group
showed increased
silver distribution
and overt
hepatobiliary
toxicity compared
to larger ones.

Sp, Li, Lu,
Ki, Bl, Br

[73]

20 nm;
110
nm

1
mg/kg

Pregnant
Sprague
Dawley
rats

Single
exposure,
sacrificed at
24-hrs and
48-hrs post
exposure

silver crosses the
placenta and is
transferred to the
fetus regardless of
the form of silver

Sp, Pl, Li, Lu,
Ce, Bl, Ki

[188]

6.3629
nm

5
mg/kg

Female
Sprague
Dawley
rats

Single
exposure,
sacrificed at
24-hrs

Histopathologically
AgNPs caused
mild irritation in
thymus and spleen
and significantly
increased
chromosome
breakage and
polyploidy cell
rates

Lu, Sp. Li,
Ki, Th, Ht

[208]

20 nm;
110
nm
(PVP
or CT)

701.75
μg/kg

Pregnant
female
Sprague
Dawley
rats

Single i.v
administration

Exposure to CTAgNPs, is
associated with
changes in fetal
growth and
increased
contractile force in
both uterine and
aortic vessels

N/A

[209]
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Chapter 2: Hypothesis, Aims and Objectives
2.1 Hypothesis
Among the various routes of exposure discussed in the introduction section,
inhalation through the lung provides a major pathway for the human exposure of
AgNPs. The latter is most likely to happen during particle synthesis, handling of dry
powders, aerosolization of liquid suspensions, along with the manufacture and
machining of composites containing AgNPs. Exposure is also probable beyond the
scope of occupational exposure, via the utilization of AgNPs in consumer products
such as disinfecting sprays or deodorants which have the potential to directly
aerosolize AgNP, which may lead to a direct pulmonary exposure to AgNPs.
Furthermore, AgNPs are a dynamic area of research of inhalable therapies for
respiratory infections and allergic airway inflammation.
Consequently, pulmonary exposure to AgNPs has received increased attention
due to their potential to cause pulmonary injury, cross the alveolar-capillary barrier as
NPs or solubilized form, and distribute to remote organs. In this context, though there
are considerable studies reporting into how pulmonary exposure to AgNPs may impact
pulmonary toxicity, the mechanism by which pulmonary deposited AgNPs may induce
pathophysiological effects on the cardiovascular system and other major remote organs
(including liver, kidney, spleen and brain) is not well understood. In addition,
understanding the interactions of AgNP coating as well as the influence of particle
doses at different post- exposure endpoints is an important, yet under investigated, step
in understanding the cardiovascular and systemic mechanisms of pulmonary exposure
to AgNPs. Furthermore, as AgNPs can translocate from the alveoli into the
bloodstream, they can, consequently, interact with erythrocytes and information
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regarding the pathophysiological effects and possible mechanism of action of AgNPs
on the erythrocytes are still inadequately studied. Hence, we hypothesize that
pulmonary deposited AgNPs could alter cardiovascular hemostasis, induce
pathophysiological effect on major distant organs, interact with erythrocytes and
induce hemolysis and eryptosis.
2.2 Aims and Objectives
The aim of the study was to investigate the following:
i) Coating (PVP and CT), post exposure time (1 day and 7-days) and dosedependent (0.05, 0.5 and 5 mg/kg) effects of pulmonary exposure to 10 nm AgNPs, on
the cardiovascular system.
ii) Coating (PVP and CT) and post exposure time (1 and 7-days) dependent
effect of pulmonary exposed 10 nm AgNPs on major distant organs including liver,
kidney, spleen and brain.
iii) In vitro effects of PVP- and CT- AgNPs (10 nm) at three different doses
(2.5, 10, and 40 µg/ml) on mouse erythrocytes in vitro.
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Chapter 3: Methods
3.1 Research design
In the present study, we, firstly, assessed the effects of pulmonary exposed 10
nm AgNPs on cardiovascular homeostasis. Secondly, we evaluated the biodistribution
and pathophysiological effects of 10 nm AgNPs in local and major remote organs
including lung, liver, kidney, brain and spleen, following pulmonary exposure.
Thirdly, we investigated the in vitro effects of AgNPs on mouse erythrocytes.
3.2 Material and Methods
Particles
Suspensions of silver nanoparticles of 10 nm (BioPureTM), coated with either
PVP or CT were purchased from NanoComposix (San Diego, CA, USA). Details
provided by the manufacturer on the physico-chemical properties of the studied
AgNPs are reported in Table 6.

45
Table 6: Main physicochemical properties of tested AgNPs provided by the
manufacturer and reported in the datasheet.
Biopure Silver
Nanoparticles

10 nm PVP
AgNPs

10 nm CT-AgNPs

Lot no.

HKE0023

JEA0236

DLS

Mean
hydrodynamic
diameter (nm)

19

14

UV-Vis

Λmax (nm)

390

389

Diameter (mean ±
SD) (nm)

10.1 ± 1.8

9.0 ± 1.7

Surface area
(m2/g)

53.5

59.0

Variation
coefficient (%)

17.5

19.2

Mas concentration
(mg/ml)

1.08

1.07

Particle
concentration
(particles/ml)

1.9E+14

2.6E+14

Endotoxin level
(EU/ml)

<5

<5

Zeta potential
(mV)

-26

-33

pH of solution

7.4

7.5

Solvent

MilliQ water

Aqueous 2 mM
citrate

TEM
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For the in vivo experiments, AgNPs exposure in Balb/C mice was achieved by
single i.t. instillation. As mice are obligate nose breathers, which results in most of the
inhaled particles being removed by filtration, we chose i.t. instillation to simulate
pulmonary exposure to NPs that enabled controlled and consistent dose deposition,
and consequently, accurate determination of dose response [210, 211]. Various cardiac
and systemic endpoints were assessed including thrombosis, inflammation, oxidative
stress, DNA damage and apoptosis following 1 and 7-days post exposure. For in vitro
experiments, we evaluated hemolytic, oxidative stress and eryptosis of mouse
erythrocytes following 4 hours incubation with 10 nm AgNPs.
The studies are structurally presented along with results and discussions in the
following section.
3.3 Study one: Pulmonary exposure to silver nanoparticles impairs
cardiovascular homeostasis: effects of coating, dose and time
3.3.1 Background
Of the various routes of introduction, pulmonary exposure to aerosolized
particles is a prime concern regarding safety of ENMs. Inhalation exposure of AgNPs
can occur at nanosilver-manufacturing industries during particle synthesis, handling
of dry powders, as well as during manufacture of AgNPs containing products. In this
regard, a study from air samples collected in the injection room of a nano-Ag
manufacturing facility showed that it is possible for workers to be exposed to airborne
AgNPs concentrations, ranging from 0.005 to 0.289 mg/m3 [212]. Beside occupational
exposure, the extensive use of AgNPs also increases the risk of consumer exposure via
inhalation of AgNPs that are used in spray application such as disinfectants,
deodorants and nebulizers [99]. Despite several studies into how pulmonary exposure
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to ENMs may impact pulmonary toxicity, there are much fewer investigations on the
impact of pulmonary exposure on extra-pulmonary targets particularly cardiovascular
toxicity [170, 175, 213]. Following pulmonary exposure, there is evidence showing
that nanoparticles (NPs) such as titanium dioxides (TiO2), nano-ceria and AgNPs may
translocate from the lung to systemic circulation and eventually be deposited in remote
organs causing toxicity [23, 167, 214]. A strong relationship between pulmonary
exposure to particulate matter and cardiovascular toxicity has been previously reported
[178, 215]. It has also been demonstrated that pulmonary exposure to other forms of
ENMs are capable of inducing or exacerbating cardiovascular dysfunction via
mechanisms including systemic inflammation, coronary artery dysfunction, metabolic
derangement, autonomic dysregulation and oxidative stress [174, 175, 216, 217].
However, the mechanism by which pulmonary exposure to AgNPs causes
cardiovascular toxicity is poorly understood.
Recent studies have demonstrated that the pathophysiological effect of AgNPs
is size, coating and dose-dependent [73, 128, 168, 173]. It is well known that smaller
sized NPs result in increased bioavailability, enhanced distribution, and toxicity of
silver compared with larger ones [73, 74]. The inverse relationship between the particle
size and surface area implies that smaller AgNPs may have a faster rate of silver ions
(Ag+) dissolution in the surrounding microenvironment [218]. Stability of NPs is also
differentially affected by the type of coating [47, 128, 173]. In this context, an appraisal
of scientific literature revealed that citrate (CT) coating of AgNPs was the most
commonly used stabilizing agent, followed by polyvinylprrolidone (PVP) and amines
[43]. However, work by Huynh et al. [219] and Tejamaya et al. [220] suggested that
PVP- coated NPs are more stable than those coated with CT. Furthermore, the
toxicological effects are also demonstrated to be influenced by dose and time of
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exposure to AgNPs [173, 221]. Until now, there has been much debate in the literature
regarding the formulation of AgNPs that leads to toxicity [222]. The adverse effects
might be the result of either the direct interaction of AgNPs themselves, or released
Ag+ ions or a combination of both [73]. Though Ag+ ions are known to have toxic
effects in various biological species, including bacteria, fungi and viruses, they are
reported to exhibit low toxicity in mammalian cells, which may be due to the formation
of insoluble salts with chloride and sulfide ions [223]. Furthermore, smaller AgNPs
(≤10 nm) have proven to be more toxic than predicted on the basis of Ag+ ion release
in the biological medium [34].
Most of the previous in vivo experiments on pulmonary exposure to AgNPs
have been limited to studying only one particle type (one coating and/ one size), at
limited dose range and/or post exposure time frame and mostly reporting effects in
lung. An aspect that has not been evaluated extensively so far is the potential
cardiovascular effect of pulmonary exposure to AgNPs. Hence, we hypothesize that
pulmonary deposited AgNPs could alter cardiovascular hemostasis and tested the
hypothesis by evaluating the impact of two different coatings (namely PVP and CT),
3 doses (0.05, 0.5 and 5 mg/kg) and 2 time points (1 and 7 days). As mice are obligate
nose breathers, which results in most of the inhaled particles being removed by
filtration, we chose i.t. instillation to simulate pulmonary exposure to NPs that enabled
controlled and consistent dose deposition, and consequently, accurate determination
of dose response [210, 211]. Following i.t. instillation, we evaluated the acute (1-day)
and sub-acute (7-days) vascular, systemic and cardiac effects of well characterized 10
nm AgNPs, using physiological parameters including a well-established mouse model
of thrombosis in pial microvessels in vivo and evaluation of several markers of
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coagulation, oxidative stress, inflammation, DNA damage and apoptosis in plasma and
heart of mice.
3.3.2 Methods
Nanoparticles, silver acetate and vehicles
Suspensions of AgNPs of 10 nm (BioPureTM), coated with either PVP or CT,
were purchased from NanoComposix (San Diego, CA, USA). The provided stock
concentrations were 1.0 mg/ml with endotoxin level <5 EU/ml and silver purity of
99.99%. The surface areas of PVP- and CT- AgNPs were 53.5 m2/g and 59.0 m2/g,
respectively. The pH of both the suspensions was 7.4. The suspending solvents of
PVP- and CT- AgNPs were sterile saline (0.9% NaCl) and 2.0 mM sodium citrate,
respectively. Silver acetate (AgAc), as the source of Ag+ ions, purchased from SigmaAldrich (#216674, St. Louis, MO, USA), was dissolved in sterile water to yield a stock
concentration of 1 mg/ml. To minimize aggregation, the working stock particle
suspensions were always sonicated (Clifton Ultrasonic Bath, Clifton, NJ, USA) for 15
min and vortexed for 30 sec before their dilution and/or instillation. The vehicle for
PVP- AgNPs and AgAc control groups was prepared as 0.9% NaCl. The vehicle for
CT- AgNPs was 2 mM sodium citrate (Sigma-Aldrich, St. Louis, MO) dissolved in
deionized water.
Characterization of AgNPs: zeta potential measurement and transmission electron
microscopy (TEM)
The size distribution and the zeta potential of the nanoparticles were analyzed
in aqueous dispersion using Malvern zetasizer instrument (Malvern Panalytical, UK),
and Zetasizer 7.11 software for the measurement and data processing. All
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measurements were carried out at room temperature and were done in triplicate. TEM
of AgNPs were performed by method described in our previous paper [118]. Briefly,
the suspensions were subjected to sonication at room temperature for 15 min prior to
processing for TEM. A drop of PVP- and CT- AgNPs suspensions were deposited on
a 200 mesh Formvar/Carbon coated copper grid and allowed to dry for 1 hr at room
temperature. Then the grids were examined and photographed at different
magnifications using FEI Tecnai Biotwin Spirit G2 TEM (FEI, Eindhovon,
Netherlands).
Animals, dosing and i.t instillation
Both male and female BALB/C mice of age 8-10 weeks (BW: 22-25g)
(Taconic Farms Inc., Germantown, NY, USA) were housed in light- (12 hrs
light: 12 hrs dark cycle) and temperature-controlled (22 ± 1°C) rooms. They had free
access to commercial laboratory chow and were provided tap water ad libitum.
The animals were randomly and broadly divided into the following groups: i)
10 nm PVP- AgNPs, ii) 10 nm CT-AgNPs, iii) ionic silver control: Ag+ ions, iv) 0.9%
NaCl (vehicle control for PVP-AgNPs and Ag+ ions and v) 2 mM citrate (vehicle
control for CT-AgNPs). For in vivo studies, the AgNPs (group i and ii) were dosed at
0.05, 0.5 and 5 mg/kg BW and Ag+ ions (group iii) at 8 mg/kg BW, which is equivalent
to the highest dose of AgNPs (5 mg/kg) used and freshly made on the day of dosing
using endotoxin free water. Each group contained 8 animals with equally distributed
male and female mice for each dose and for each endpoint i.e. 1 and 7 days. In the case
of in vitro analysis, while the concentrations prepared for AgNPs were 0.04, 0.2 and 1
µg/ml, the Ag+ ion concentration used was 1.55 µg/ml, equivalent to the highest dose
of AgNPs i.e. 1 µg/ml.
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The in vivo concentrations used in our study may not reflect a practical standard
of human exposure; however, they are comparable with those employed in previous
animal models of i.t. administration of AgNPs [73, 173]. Considering various factors
such as American Conference of Governmental Industrial Hygienists limits for soluble
and insoluble silver (0.01 mg/m3 and 0.1 mg/m3 respectively), occupational exposure
measured at 1.02 µg/m3 and estimated dose of 75 ng AgNPs from consumer product
(2.43 µg/m3 and 1.02 µg/m3 for soluble and insoluble silver, respectively), the doses
tested in the present study correlate to potential human exposure in countries where
occupational safety is not much considered [212, 224]. A study in silver manufacturing
plant has shown that AgNPs in the air increases during production and peak area
concentration of more than 290 µg/m3 has been detected and the later concentration
has been used to correlate our in vivo doses [212]. The alveolar epithelium surface area
in human is more than 102 m2 [225] and ventilation rate is 20 l/min. Hence, exposure
to 290 µg/m3 AgNPs would produce more than 11, 55 and 218 µg AgNPs/m2 alveolar
epithelium after 1 day, 1week and 1month, respectively. The alveolar epithelium
surface area of mouse is more than 0.05 m2 [225], hence, the in vivo concentration
used in this study; i.e. 0.05, 0.5 and 5 mg/kg would result in 25, 250 and 2500 µg
AgNPs/m2, respectively, in a mouse weighing an average of 25 g. These doses
approximate human occupational exposure to AgNPs after 2 days, 5 weeks and 11
months. As our preliminary analysis showed that animals given the highest dose of
AgNPs exhibited much more of a significant effect, we chose a concentration of Ag+
ions to be tested equivalent to the highest dose of AgNPs. Similar derivation of the
equivalent dose for Ag+ ions has been used recently by Recordati et al. [73]. We related
our in vitro doses to in vivo doses used in current study. If at least 10% of the instilled
AgNPs is expected to translocate to the systemic circulation [226, 227] for a mouse
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weighing an average of 25 g, the concentration that would be available after the highest
in vivo dose instillation, which is 5 mg/kg, would be approximately 12 µg/ml.
However, we used a much lower in vitro concentration in our study, the highest dose
(1 µg/ml) representing 1.6% of the pulmonary instilled dose.
Pulmonary exposure was achieved by single i.t. instillation. Mice were
anesthetized with isoflurane and placed supine with extended neck on an angled board.
A Becton Dickinson 24 Gauge cannula was inserted via the mouth into the trachea.
The NPs suspension, AgAc or vehicles was instilled (100 µL) via a sterile syringe,
followed by an equal volume of air bolus. Following 1 and 7-days of pulmonary
exposure to AgNPs, Ag+ ions or vehicles, mice were sacrificed with an overdose of
sodium pentobarbital, lung inflammation and several cardiovascular events were
assessed.
For each AgNPs type a sample size of 64 mice and for Ag ions group a sample
size of 36 mice were used for pial vessel thrombosis study. Subsequent studies were
completed using additional 64 and 36 animals for each NP type and Ag+ ions
respectively, for lung pathology, determination of systemic markers of inflammation
and cardiac apoptosis. Another set of 32 animals for each AgNPs type were used to
study markers of coagulation and in vitro platelet aggregation. Animals were sacrificed
with an overdose of sodium pentobarbital, after 1 day and 7-days single i.t.
administration of either vehicle or AgNPs or Ag+ ions.
This study was reviewed and approved by the Institutional Review Board of
the United Arab Emirates University, College of Medicine and Health Sciences, and
experiments were performed in accordance with protocols approved by the
Institutional Animal Care and Research Advisory Committee.
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Histology of lungs
Lungs were excised, washed with ice-cold saline, blotted with filter paper and
weighed. Each organ was dissected, casseted and immediately fixed in 10% neutral
formalin for 24 hours, which was followed by dehydration in increasing concentrations
of ethanol, cleared with xylene and embedded with paraffin. Five- µm sections were
prepared from paraffin blocks and stained with hematoxylin and eosin (H & E) [228].
The stained sections were evaluated using light microscopy by the histopathologist
who participated in this project.
Measurement of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) in heart
Immediately after sacrifice, the harvested heart was quickly rinsed with icecold PBS (pH 7.4) before homogenization in 0.1 M phosphate buffer, pH 7.4,
containing

0.15 M

KCl,

0.1 mM

EDTA,

1 mM

DTT,

and

0.1 mM

phenylmethylsulfonyl fluoride at 4°C. The homogenates were centrifuged at
14,000 rpm for 20 min at 4°C to remove cellular debris, and the supernatants were
stored for biomolecular analysis [229]. The total concentration of protein was
determined using bicinchoninic acid assay (BCA assay). TNF-α and IL-6 were
measured using ELISA Kits (Duo Set, R & D systems, Minneapolis, MN, USA).
Oxidative stress and lipid peroxidation evaluation: Detection of total antioxidants,
reduced glutathione (GSH) and 8 –isoprostane in heart
Total antioxidant was assayed by a commercially available kit (Cayman, Ann
Arbor, MI, USA) according to the manufacturer’s instruction. The concentration of
GSH was also measured using a commercially available kit (Sigma-Aldrich Fine
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Chemicals, St Louis, MO, USA), as were 8-isoprostane concentrations (ELISA Kit,
Cayman Chemicals, Michigan, USA) [230].
Oxidative DNA damage evaluation by measurement of 8-hydroxy-2-deoxyguanosine
(8-OH-dG) in heart
8-OH-dG was quantified using an ELISA kit (Cayman, Ann Arbor, MI, USA)
according to the manufacturer’s instruction [231].
Detection of apoptosis in heart
Apoptotic myocytes were detected by terminal deoxynucleotide transferase
mediated dUTP nick end-labelling (TUNEL) assay, using a TACS® 2 TdT
diaminobenzidine (DAB) kit (Trevigen, Gaithersburg, MD, USA) according to the
manufacturer’s instruction [232]. Briefly, paraffin embedded heart tissues were cut
into 5 µm sections and deparaffinized with xylene followed by rehydration with
decreasing concentrations of ethanol. Rehydrated tissue sections were washed with
PBS and incubated with proteinase K for 15 min at room temperature, washed and
quenched with hydrogen peroxide before labeling with biotin labeled dUTP for 1 hr at
37°C. The labeling reaction was stopped by adding stop buffer as provided by the kit.
The tissue sections were then incubated with horseradish peroxidase-conjugated
streptavidin for 10 min at 37°C, washed, and immersed in DAB solution for color
development. These sections were also counterstained with methyl green before
mounting. Negative control of the TUNEL assay was confirmed by staining of the
heart tissue in the same manner without labelling enzyme. The positive control of the
TUNEL assay was confirmed by staining heart sections with a labelling mix that
contained TACS-nucleaseTM. Preparations were observed and photographed using a
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light microscope. Cells with green nuclei after TUNEL staining using methyl green
were considered normal, whereas cells with brown nuclei were considered apoptotic.
Apoptotic (TUNEL positive) cells were counted in at least ten areas per heart section,
in eight individual sections from each animal, at 400X magnification.
Measurement of systemic markers of coagulation and fibrinolysis
The concentrations of fibrinogen (Molecular Innovation, Southfield, MI, USA)
and plasminogen activation inhibitor (PAI-1, Molecular Innovation, Southfield, USA)
were determined using an ELISA Kit. Brain natriuretic peptide (BNP), Phoenix
Pharmaceuticals, Burlingham, California, USA) was measured spectrophotometrically
using ELISA kits.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT)
measurements in plasma
The PT and aPTT were measured in plasma collected from treated mice by
using TEClot PT-S and TEClot APTT-S kits (TECO GmbH, Dieselstr. 1, 84088,
Neufahrn, NB, Germany), according to the manufacturer’s instruction. Briefly, the PT
and aPTT were measured in platelet poor plasma (PPP), pre- incubated at 37°C for 3
min, followed by addition of PT and aPTT reagent, using a Merlin coagulometer (MC
1 VET, Merlin, Lemgo, Germany).
Experimental pial arterioles and venules thrombosis model
In separate animals, in vivo thrombogenesis in the pial arterioles and venules
was assessed after AgNPs and Ag+ ions exposure at the end of 1 and 7 days, according
to a previously described technique [228]. Briefly, the animal was anesthetized with
urethane (1 mg/g BW, i.p.), the trachea was intubated, and the right jugular vein was
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cannulated with a 2F venous catheter (Portex, Hythe, UK) for the administration of
fluorescein (Sigma, St. Louis, MO, USA). Thereafter, craniotomy was first performed
on the right temporoparietal cortex with a hand‐held microdrill, and the dura was
stripped open. Only untraumatized preparations were used, and those showing trauma
to either microvessels or underlying brain tissue were discarded. Cerebral
microcirculation was directly visualized using a fluorescence microscope (Olympus,
Melville, NY, USA) connected to a camera and DVD recorder. A heating pad was
used, and body temperature was raised to 37°C, as monitored by a rectal thermoprobe
connected to a temperature reader (Physitemp Instruments, NJ, USA). A field
containing arterioles and venules 15-20 µm in diameter was chosen. Such a field was
taped prior to, and during the photochemical insult, which was carried out by injecting
fluorescein (0.1 ml/mouse of 5% solution) via the jugular vein, which was allowed to
circulate for 30-40 sec. The cranial preparation was then exposed to stabilized mercury
light. The photochemically induced injury to arterioles and venules, in turn, causes
platelets to adhere at the site of endothelial damage and aggregate. Platelet aggregates
and thrombus formation grow in size until complete vascular occlusion. The time from
the injury until complete vascular occlusion (time to flow stop) in arterioles and
venules was measured in seconds. At the end of the experiments, the animals were
euthanized by an overdose of urethane.
In vitro platelet aggregation in mouse whole blood
The platelet aggregation assay in whole blood was performed as described in
previous studies [228]. After anesthesia, blood from untreated mice was withdrawn
from the inferior vena cava, placed in citrate (3.2%), and 0.1 mL aliquots were added
to the well of a Merlin coagulometer (MC 1 VET; Merlin, Lemgo, Germany). The
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blood samples were incubated at 37°C or 3 minutes and then stirred for another 3
minutes with either PVP- or CT- AgNPs at concentrations of 0.04, 0.2, or 1 μg/mL or
Ag+ ions at 1.55 μg/mL. The control for PVP- AgNPs and Ag+ ions was saline, while
for CT-AgNPs it was 2 mM citrate solution. At the end of this period, single platelets
were counted in a VET ABX Micros with a mouse card (ABX, Montpellier, France).
The degree of platelet aggregation following NPs and Ag+ ions exposure was
calculated as a fall in the number of single platelets counted and expressed as a % of
respective controls.
Statistics
Data are presented as mean ± standard error of the mean and the statistical
significance was determined by one-way analysis of variance (ANOVA) followed by
the Holm-Sidak comparison test. P ≤ 0.05 were regarded as significant using GraphPad
Prism Ver. 5.01 (GraphPad Software Inc., La Jolla, CA, USA).
3.3.3 Results
Characterization of PVP- and CT- AgNPs
The TEM analysis showed primary particle of size ≈ 10 nm for both coating
types (Figure 2). Agglomerated clusters were also seen (Figure 2 A & D). The results
of size distribution and zeta potential measurements are represented in Table 7 and
Figure 2 (B, C, E & F). Both PVP- and CT-coated AgNPs showed agglomeration with
an average size of 93.2 ± 3.4 nm for PVP-AgNPs and 62.1 ± 0.27 nm for CT-AgNPs,
and a highest particle size of 194.6 ± 3.2 nm for PVP-AgNPs and 157.9 ± 32.1 nm for
CT-AgNPs . The Zeta potential for PVP-AgNPs was found to be - 0.305 ± 0.09 mV,
whereas that of CT-AgNPs was - 36.25 ± 1.2.
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Table 7: Size distribution and zeta potential measurements of polyvinylpyrrolidone
(PVP) and citrate coated silver nanoparticles (AgNPs).
Average size (nm)

Highest particle size

Zeta potential (mV)

(nm)
PVP-AgNPs

93.2 ± 3.4

194.6 ± 3.2

- 0.305 ± 0.09

CT-AgNPs

62.1 ± 0.27

157.9 ± 32.1

- 36.25 ± 1.2

Data are mean ± SEM (n=3).
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B

C

Figure 2: Transmission electron microscope analysis of polyvinylpyrrolidone
or citrate coated silver nanoparticles. Representative images showing size
distribution and zeta potential measurements of polyvinylpyrrolidone (PVP)
or citrate (CT) coated silver nanoparticles (AgNPs).
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D

E

F

Figure 2: Transmission electron microscope analysis of polyvinylpyrrolidone (A) or
citrate (D) coated silver nanoparticles. Representative images showing size
distribution and zeta potential measurements of polyvinylpyrrolidone (PVP) or citrate
(CT) coated silver nanoparticles (AgNPs) (cont’d).
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Histopathological examinations
Light microscopy analysis of the lung sections stained with H&E obtained
from control mice (0.9% NaCl and 2 mM citrate) exhibited normal structure (Figure 3
A & B). Compared with their respective controls, there was marked increase of
inflammatory infiltrate in the lung sections of mice i.t. instilled with either PVP- or
CT- AgNPs at all doses (0.05, 0.5, and 5 mg/kg) and at both endpoints (1 and 7-days).
The inflammatory infiltrate consisted of neutrophil polymorphs, macrophages, and
lymphocytes. The intensity of infiltrate was almost similar after 1 and 7-days of
exposure of any of the 3 doses for both the PVP- and CT- AgNPs group. Likewise,
compared with the control there was mild peribronchial inflammatory cells infiltration
consisting of neutrophil polymorphs and lymphocytes, following 1 and 7-days of i.t.
instillation of Ag+ ions (figure not shown).
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Figure 3: Representative light microscopy sections of lung tissues of control mice and
those treated with polyvinypyrrolidine (PVP) silver nanoparticles (AgNPs) at dose of
0.05, 0.5, 5 mg/kg, stained with H&E (A) and of control mice and those treated with
citrate (CT) silver nanoparticles (AgNPs) at dose of 0.05, 0.5, 5 mg/kg, stained with
H&E (B). All magnifications: 400X. The control group shows normal lung
architecture and histology. PVP- and CT- AgNPs treated group shows increased
interstitial inflammatory cells following 1-day and 7-days of intratracheal instillation
of any of the three doses in alveolar and bronchial walls. The inflammatory infiltrate
consists of neutrophil polymorphs (arrowhead), macrophages (thick arrow) and
lymphocytes (thin arrow).

Effect of AgNPs and Ag+ on cytokines concentrations in heart homogenates
Concentrations of TNF-α and IL-6 are shown in Figure 4. After 1-day
exposure, the administered AgNPs caused a dose-dependent increase in the levels of
TNF-α in heart for both coating types (Figure 4 A). The increase was statistically
significant at 5 mg/kg (P < 0.001) for the PVP group, and at all concentrations for CTAgNPs (P < 0.05). Similarly, Ag+ significantly augmented the level of TNF-α (P <
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0.001). In comparison with the control group, AgNPs caused significant increase of
IL-6, at 5 mg/kg (P < 0.001) for PVP- and at 5 mg/kg (P < 0.05) for CT- AgNPs (Figure
4 C). The increase was significant for animals treated with Ag+ ions (P < 0.001) also.
Interestingly, no significant effect was observed at any of the concentrations for any
of the particles following 7-days of i.t. instillation (Figure 4 B &D).
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Figure 4: TNF-α and IL-6 levels in heart tissues following 1 day and 7 days of intratracheal instillation of saline (control) or citrate 2 mM (control) or
polyvinylpyrrolidine (PVP) or citrate (CT) silver nanoparticles (AgNPs) or silver
acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each group).
Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.
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Effect of AgNPs and Ag+ ions on oxidative stress markers in heart homogenates
The assessments of total antioxidants, GSH and 8-isoprostane following the
exposure to PVP- and CT- AgNPs and Ag+ are represented in Figure 5. Following 1day exposure, a dose-dependent increase of total antioxidants was observed for both
PVP- and CT- AgNPs (Figure 5 A). While the level of significance was achieved at
0.5 mg/kg (P < 0.01) and 5 mg/kg (P < 0.001) for PVP- AgNPs, the CT group showed
significant increase at 5 mg/kg (P < 0.01). A significant increase was also observed for
Ag+ ions (P < 0.001). After 7-days, a dose-dependent increase was found for both
coating particles with significance achieved at the highest dose (P < 0.05) (Figure 5
B). The effect remained significant for Ag+ ions (P < 0.05). Compared with the control
group, PVP- AgNPs caused an acute dose-dependent increase in GSH at 0.05 mg/kg
(P < 0.01), 0.5 mg/kg (P < 0.001) and 5 mg/kg (P < 0.001) (Figure 5 C). Likewise, CTAgNPs caused a significant increase at 0.05 mg/kg (P < 0.05) and 5 mg/kg (P < 0.01).
Ag+ ions also produced significant increase (P < 0.001) compared with control. In the
case of 8-isoprostane measurement, a dose-dependent increase was observed
following 1-day treatment (Figure 5 E); significance was achieved at 5 mg/kg (P <
0.001) for PVP coated and at 5 mg/kg (P < 0.01) for CT coated AgNPs. After 7 days,
significant increase of 8-isoprostane was only seen with PVP coating at 5 mg/kg (P <
0.05) (Figure 5 F). Interestingly, Ag+ ions did not produce any acute effect, but showed
a significant increase (P < 0.001) after 7-days treatment.
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Figure 5: Total antioxidants (A, B), reduced glutathione (GSH, C, D) and 8-isoprostane
(E, F) levels in heart tissues following 1 day and 7 days of intra-tracheal instillation of
saline (control) or citrate 2 mM (control) or polyvinylpyrrolidine (PVP) or citrate (CT)
silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM
(n = 6-8 in each group). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.
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Effect of AgNPs and Ag+ ions on 8-OH-dG concentrations in heart homogenates
Figure 6 shows the concentration of 8-OH-dG in heart following 1 and 7 days
of i.t. instillation of either AgNPs or Ag+. Following 1-day exposure, the concentration
of 8-OH-dG increased dose-dependently for PVP- and CT- AgNPs (Figure 6 A). The
level of significance was achieved at 0.5 mg/kg (P < 0.05) and 5 mg/kg (P < 0.01) in
the case of PVP- AgNPs and at the highest dose for CT- AgNPs (P < 0.001). The
significant effect persisted at 7 days with PVP- AgNPs at 0.5 mg/kg (P < 0.01) and 5
mg/kg (P < 0.001) (Figure 6 B). No effect on 8-OH-dG was observed with Ag+ ions at
both time points.

Figure 6: 8-hydroxy-2-deoxyguanosine (8-OH-dG, A, B) levels in heart tissues
following 1 day and 7 days of intra-tracheal instillation of saline (control) or citrate 2
mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles
(AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each
group). Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.

68
Measurement of cardiac cell apoptosis
Figure 7 represents percentage of tunel positive cardiomyocytes with the
representative images for all particles and doses. A dose-dependent increase was
observed, with significance being achieved at the highest dose; PVP- AgNPs (P < 0.05)
and CT- AgNPs (P < 0.01) following 1-day exposure and only PVP-AgNPs (P < 0.05)
after 7-days exposure. No significant effects were attained with Ag+ ions.
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1 day

1 day

Figure 7: Estimation of apoptotic cells by an in situ TUNEL assay in heart sections
and their representative images, following intra-tracheal instillation of saline (control)
or citrate 2 mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver
nanoparticles (AgNPs) or silver acetate (AgAc) in mice. The inset images are
represented by yellow arrows. Counts of apoptotic cells were made in the sections
(n=7-8 per group) at a final magnification of X200 and the average of apoptotic cell
numbers in per group were calculated.
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7 days

7 days

Figure 7: Estimation of apoptotic cells by an in situ TUNEL assay in heart sections
and their representative images, following intra-tracheal instillation of saline (control)
or citrate 2 mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver
nanoparticles (AgNPs) or silver acetate (AgAc) in mice. The inset images are
represented by yellow arrows. Counts of apoptotic cells were made in the sections
(n=7-8 per group) at a final magnification of X200 and the average of apoptotic cell
numbers in per group were calculated (cont’d).
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Effect of AgNPs and Ag+ ions on fibrinogen and PAI-1 concentrations in plasma
Figure 8 represents the plasma concentration of fibrinogen and PAI-1. After 1day of exposure, a significant increase in fibrinogen (Figure 8 A) was obtained at 0.05
mg/kg (P < 0.01), 0.5 mg/kg (P < 0.01) and 5 mg/kg (P < 0.05) for PVP- AgNPs. For
CT- AgNPs the effect was significant at 0.5 mg/kg (P < 0.01) and 5 mg/kg (P < 0.05)
compared with the control. The effect was significant for Ag+ (P < 0.001). Following
7-days exposure, there was an increase in fibrinogen for both type of AgNPs and Ag+
ions compared with their respective controls (Figure 8 B). However, the significance
was achieved only for CT- AgNPs at 0.05 mg/kg (P < 0.05) and 5 mg/kg (P = 0.001).
PVP- AgNPs significantly increased PAI-1 at 0.05 mg/kg (P < 0.001), 0.5
mg/kg (P = 0.05) and 5 mg/kg (P < 0.001), post 1-day exposure (Figure 8 C). The
significant effect for CT- AgNPs was seen at 0.05 mg/kg (P < 0.05) and 5 mg/kg (P <
0.001). At the 7-days time point (Figure 8 D), an increase of PAI-1 was observed in
all doses; however, the significance was achieved for PVP- AgNPs at 0.5 mg/kg (P <
0.01) and 5 mg/kg (P < 0.001), and for Ag+ (P < 0.001).
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Figure 8: Fibrinogen (A, B) Plasminogen activator inhibitor-1 (PAI-1, C, D)
concentrations in plasma, following 1-day and 7-days of intra-tracheal instillation of
saline (control) or citrate 2 mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT)
silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM
(n = 6-8 in each group). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.

Effect of AgNPs and Ag+ ions on BNP concentrations in plasma
Figure 9 illustrates the plasma concentration of BNP following 1 and - days of
i.t. instillation of either AgNPs or Ag+. Increase of BNP was observed for all particle
types following 1-day exposure, though the significance was only attained at 5 mg/kg
(P < 0.05) for PVP- AgNPs and at 0.5 mg/kg (P < 0.05) and 5 mg/kg (P < 0.05) for
CT- AgNPs, compared with their respective controls (Figure 9 A). Post 7 days
exposure, a significant increase (P < 0.05) was achieved at the highest dose for both
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particle types compared with their respective controls (Figure 9 B). However, Ag+ ions
did not increase BNP concentrations at these time points.

Figure 9: Plasma brain natriuretic peptide (BNP) (A, B) following 1-day and 7-days
of intra-tracheal instillation of saline (control) or citrate 2 mM (control) or
polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles (AgNPs) or silver
acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each group). Statistical
analysis by one-way ANOVA followed by Holm-Sidak’s multiple comparison test.

Effect of AgNPs and Ag+ ions on PT and aPTT in vitro
Figure 10 illustrates the PT and aPTT in PPP collected from mice treated with
either AgNPs or Ag+ ions. Compared with the control group, a significant and dosedependent reduction in PT was observed with both coating NPs, following 1-day
exposure (Figure 10 A). For PVP- AgNPs, the effect was statistically significant at all
concentration studied (P < 0.001). For CT- AgNPs the statistical significance was
obtained at 0.05 mg/kg (P <0.01), 0.5 mg/kg (P < 0.001) and 5 mg/kg (P < 0.001). The
effect was also significant for Ag+ ions (P < 0.001). Post 7-days exposure (Figure 10
B), a significant reduction of PT was obtained in the PVP group at 0.05 mg/kg (P <
0.001), 0.5 (P < 0.001) and 5 mg/kg (P = 0.01) compared with the control. In the case
of CT- AgNPs, the level of significance was achieved at 0.05 mg/kg (P < 0.001) and
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5 mg/kg (P < 0.05). The effect was significant for Ag+ ions (P < 0.001). After 1-day
exposure (Figure 10 C), PVP- AgNPs induced a significant shortening of aPTT at all
concentrations (P < 0.001). CT-AgNPs reduced the aPTT at 0.5 mg/kg (P < 0.001).
Ag+ ions also caused a reduction (P < 0.001) compared with the control. Following 7days of i.t. instillation (Figure 10 D), a significant reduction of aPTT was achieved at
0.05 mg/kg (P < 0.001) for PVP- AgNPS and at 0.05 mg/kg (P < 0.001) and 0.5 mg/kg
(P < 0.001) for CT- AgNPs, compared with their respective controls. Ag+ also induced
a significant effect (P < 0.001).

Figure 10: Prothrombin time (PT, A, B) and activated partial thromboplastin time
(aPTT, C, D) measured following 1-day and 7-days of intra-tracheal instillation of
saline (control) or citrate 2 mM (control) or polyvinylpyrrolidine (PVP) or citrate (CT)
silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM
(n = 6-8 in each group). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.
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Effect of AgNPs and Ag+ ions on photochemically-induced thrombosis in pial
arterioles and venules of mouse in vivo
Figure 11 illustrates the effect of PVP- or CT- AgNPs, or Ag+ ions on
thrombotic occlusion time. Both PVP- and CT- AgNPs induced significant dosedependent shortening of the thrombotic occlusion time at both time points. In the case
of arterioles, following 1-day exposure (Figure 1 1A), the level of significance was
achieved at all tested doses (P < 0.001) for PVP- AgNPs , and for CT- AgNPs the
significance was obtained at 0.05 mg/kg (P < 0.05), 0.5 mg/kg (P < 0.001) and 5 mg/kg
(P < 0.001) compared with their respective controls. In venules (Figure 11 B), the
effect was significant for all concentrations (P < 0.001) of PVP- AgNPs compared with
the control. In the case of CT- AgNPs, the effect was significant at 0.05 mg/kg (P <
0.01), 0.5 mg/kg (P < 0.01) and 5 mg/kg (P < 0.001) compared with the control.
Following 7-days post i.t. instillation (Figure 11 C), a significant shortening of
thrombotic occlusion time in the arterioles at doses of 0.05 mg/kg (P < 0.05), 0.5 mg/kg
(P < 0.01) and 5 mg/kg (P < 0.001) was observed for PVP- AgNPs. For CT- AgNPs
the effect was significant at 0.05 mg/kg (P < 0.05), 0.5 mg/kg (P < 0.01) and 5 mg/kg
(P < 0.001). In venules (Figure 19 D), while for the PVP group the effect was
significant at 0.05 mg/kg (P < 0.01), 0.5 mg/kg (P < 0.01) and 5 mg /kg (P < 0.001),
the CT- AgNPs showed significance at 0.5 mg/kg (P < 0.01), 0.5 mg/kg (P < 0.001)
and 5 mg/kg (P < 0.001) compared with their respective controls. Significant
shortening was also achieved by Ag+ ions at 1 (P < 0.001) and 7 (P < 0.05) days
respectively, compared with the control.
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Figure 11: Thrombotic occlusion time in pial arterioles or venules following 1-day (A,
B) and 7-days (C, D) of intra-tracheal instillation of saline (control) or citrate 2 mM
(control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles (AgNPs)
or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each group).
Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.

Effect of AgNPs and Ag+ ions on platelet aggregation in whole blood in vitro
Figure 12 illustrates the effect of either AgNPs or Ag+ ions on platelet
aggregation in whole blood. The in vitro treatment of whole blood from untreated mice
with either PVP- or CT- AgNPs at various concentrations caused a significant dosedependent reduction of platelet count compared with their respective controls. The
effect was significant at 0.04 µg/mL (P < 0.05), 0.2 µg/mL (P < 0.05) and 1 µg/mL
(P < 0.01) for PVP- AgNPs compared with the control. Likewise, statistical
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significance was also obtained for CT- AgNPs at 0.2 µg/mL (P < 0.05) and 1 µg/mL
(P < 0.05) compared with the control. The effect was also significant for the whole
blood treated with Ag+ at 1.55 µg/mL compared with the control.
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Figure 12: In vitro effect after the administration of saline (control) or citrate 2 mM
(control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles (AgNPs)
or silver acetate (AgAc) on platelet aggregation in whole blood of untreated mice.
Platelet aggregation in untreated whole blood 3 min after the addition of either saline
or PVP- AgNPs or CT- AgNPs was assessed. The degree of platelet aggregation
following AgNPs and AgAc exposure was expressed as a percent of control. Data are
mean ± SEM (n = 4). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.

3.3.4 Discussions
In this study, we evaluated the pathophysiological responses after single i.t.
instillation of 10 nm AgNPs considering 2 different coatings (PVP and CT), three
doses (in vivo: 0.05, 0.5 and 5 mg/kg BW, in vitro: 0.04, 0.2 and 1 µg/ml) and 2 time
endpoints (1 and 7 days) in plasma and heart of BALB/C mice. Our findings showed
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that AgNPs can induce acute dose-dependent cardiovascular effects including
thrombosis, oxidative stress, inflammation, coagulation and apoptosis, with some of
the effects being detected even after 7-days.
Characterization of test particles is a prerequisite to interpret scientific data. In
the present study, besides the TEM, the size distribution and the zeta potential of the
NPs were analyzed using Malvern zetasizer instrument. The TEM analysis showed
individual particle size of ~10 nm and agglomerated clusters. The size distribution
analysis revealed that both PVP- and CT-coated NPs showed agglomeration with a
homogeneous size distribution of the agglomerates around 100 nm. This is in
accordance with the TEM results. The PVP- AgNPs showed a zeta potential of -0.3
mV onto their surfaces, which indicates the charge close to neutrality of the AgNPs as
depicted by the un-ionized PVP coating [219]. On the other hand, the negative values
of CT- AgNPs (-36 mV) could be related to the presence of ionized carboxylate groups
onto the surface of the Ag NPs [219].
NPs translocation to the systemic circulation after pulmonary exposure and
their consequent effects on remote organs have been previously reported [166]. In this
context, there is current literature evidence that pulmonary exposure to particulate
matter and ENMs can lead to progression of cardiovascular dysfunction through
pathways including inflammation and oxidative stress [175, 233]. In our study, we
administered the AgNPs i.t., in order to ensure equivalent dosing for each animal.
Compared with inhalation, which is a natural route of human exposure to consumer
products, i.t. instillation is a preferred method of administration with the aim to address
specific endpoints regarding the toxicity of nanomaterials [210, 211].The size of the
particle has been reported to play a critical role in NP-induced toxicity; size ≤ 20 nm
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AgNPs induces greater inflammatory response and increased cytotoxicity [41, 73, 128,
168, 173]. Hence, we presently assessed the impact of 10 nm AgNPs with 2 different
coatings, namely PVP and CT.
Our histological data show that exposure to PVP- or CT- AgNPs or Ag+ ions
triggered lung inflammation substantiated by interstitial infiltration of inflammatory
cells consisting of neutrophils, lymphocytes and macrophages. All the observed effects
persisted after 7 days of instillation and this corroborates the results of Silva et al. who
demonstrated persistence of inflammatory infiltrates at 7 days post exposure of either
PVP- or CT- AgNPs [173]. Similar to their findings, no differences were noted
between animals administered AgNPs with different coatings. Compared with AgNPs,
Ag+ ions produced a milder inflammatory response consisting mainly of neutrophil
polymorphs and lymphocytes. Hence, the cardiovascular effects herein obtained by
subsequent assays could be attributed to either the AgNPs themselves or inflammation
induced or due to the release of Ag+ ions [234].
Our recent in vitro study on mouse erythrocytes demonstrated that AgNPs can
induce hemolysis via mechanisms like oxidative stress and increase cytosolic Ca2+
[118]. Additionally, several previous data suggested a link between ENMs and
cardiovascular events [235]; these effects were explained by the capacity of NPs to
induce lung inflammation, subsequently causing systemic inflammation and oxidative
stress, and/or the capacity of the NPs to translocate and enter the blood and affect
cardiovascular endpoints [178, 236]. Nevertheless, the systemic effects of AgNPs
following pulmonary exposure are not fully understood, particularly their possible
impact on cardiovascular response. This study evaluated the cardiac effect of
pulmonary exposed AgNPs by measuring markers of inflammation, oxidative stress
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and DNA damage in heart. A direct correlation between inflammatory cytokines and
myocardial injury has been previously reported in studies using silica, zinc oxide and
TiO2 NPs [237-239]. In this context, our study revealed a significant and a dosedependent increase of two of the major pro-inflammatory cytokines, TNF-α and IL-6,
following 1-day instillation of PVP- and CT- AgNPs. Increase in TNF-α and IL-6 have
been reported to induce inflammation in cardiovascular system and cause
cardiotoxicity in studies using various NPs including silica, zinc oxide and TiO2
[240].The treatment with an ionic form of Ag+ also resulted in significant increase of
the TNF-α and IL-6, post 1-day exposure. Oxidative stress, characterized by the
formation of a wide range of reactive oxygen species, is a key pathological process in
a variety of disease conditions affecting various organs such as the lung, heart, kidney
and liver. It subsequently results in DNA, protein, and lipid damage leading to cellular
dysfunction and death [241]. Our data reveal that PVP- AgNPs cause more significant
and dose dependent increase in total antioxidants and GSH compared with CT-AgNPs.
The effect however declined 7-days post exposure, except for the highest dose of both
AgNPs in the case of total antioxidants. Conversely, Ag+ ions caused a significant
decrease of GSH post 7-days i.t. instillation indicating that the particulate and ionic
form of silver may act by a different mechanism. Our data also show that exposure to
AgNPs induced a significant increase of 8-isoprostane in the heart, a marker of lipid
peroxidation. This derangement of oxidative biomarkers is in line with previous
reports which showed that silver as well as other metallic NPs, including iron and
silica, promoted cardiac oxidative stress [213, 239, 242, 243]. The effect of AgNPs on
DNA damage in the heart has never been reported so far in vivo. In this case, we
evaluated DNA damage in heart by measuring 8-OH-dG levels and apoptosis by
TUNEL assay. 8-OH-dG is one of the predominant forms of free radical induced
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oxidative lesions, and has therefore been widely used as a biomarker for oxidative
damage to DNA [244]. Increase in 8-OH dG levels was reported in liver, brain, and
kidney following administration of TiO2, gold or iron oxide NPs [245-247]. Our work
revealed an increase in 8-OH-dG in heart at the higher two doses of PVP and the
highest dose of CT- AgNPs. The increase remained significant for PVP- AgNPs even
after 7-days of exposure. However, Ag+ ions revealed no significant difference
indicating that the oxidative DNA damage effect obtained could be NP dependent.
TUNEL assay is one of the most widely used methods for detecting apoptotic cells in
situ and is based on the ability of the enzyme terminal deoxynucleotidyl transferase to
incorporate labelled dUTP into free 3′-hydroxyl termini generated by the
fragmentation of DNA [248]. Our data show significant increase in tunel positive
cardiomyocytes at the highest doses of PVP- and CT-AgNPs following 1-day after
instillation and the results are relatable to our finding of 8-OH-dG level. However, Ag+
ions did not show any effect. Overall, PVP- and CT- AgNPs induced oxidative stress
in heart evidenced by an increase of total antioxidants, GSH and 8-isoprostane, and
caused cardiac DNA damage, thereby reinforcing the previously established
mechanisms of DNA damage caused by reactive oxygen species and eventually
resulting in cellular dysfunction and apoptosis [238, 249].
Further, we evaluated the impact of AgNPs on BNP concentration in the
plasma and coagulation by measuring several endpoints, i.e., thrombosis in pial
arterioles and venules in vivo, measurement of plasma concentrations of fibrinogen,
PAI-1, PT, aPTT and in vitro platelet aggregation. Several studies demonstrated that
exposure to ultrafine particles or diesel exhaust particles (DEPs) caused thrombotic
complications and in this context, animal models of endothelial injury enables to
understanding the mechanism by which particulate matter interact with the vascular
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system [235, 250, 251]. To our knowledge, the effect of PVP- and CT- AgNPs on an
animal model of thrombosis in vivo has not been reported so far. The data of the present
study show that single i.t. administration of AgNPs (PVP or CT) induced a significant
and a dose-dependent shortening of the thrombotic occlusion time in pial arterioles
and venules, following 1 and 7-days, indicating that AgNPs possess prothrombotic
effects, which persist even after a week of exposure. Along with thrombosis in vivo, a
dose-dependent and significant increase in the concentrations of the coagulation factor,
fibrinogen and PAI-1 in the plasma following 1-day i.t. instillation of AgNPs was
found. Fibrinogen is an essential factor for clot formation [252]. PAI-1 is a potent
endogenous serine proteinase inhibitor of fibrinolysis and its relationship with
cardiovascular diseases is well established [253, 254]. Either one or both factors have
been reported to increase following exposure to DEPs, silica NPs, carbon nanotubes
and cerium oxide [228, 255, 256]. Interestingly, BNP that is normally present in low
concentration in blood and a potential marker of cardiotoxicity [257, 258] also showed
significant increase with the highest dose, for both coating NPs, at both the time points.
Similar to AgNPs, Ag+ ions showed significant effect with respect to thrombosis and
level of fibrinogen. Contrarily, with Ag+ ions, PAI-1 showed significant increase
following post 7 days of exposure and there was no effect in the level of BNP. Based
on the work on pulmonary toxicity of instilled AgNPs, Seiffert et al. suggested that
surfactant interaction stabilized the surface conditions, preventing oxidation, which
would otherwise lead to the release of Ag+ ions [179]. This might explain the dissimilar
pattern of toxicity between AgNPs and Ag+ ions and also possibly suggest that the
effect obtained in our study may be related primarily to AgNPs themselves rather than
Ag+ ions. In order to determine which of the coagulation pathways, if any, could be
affected, we evaluated the plasma PT and aPTT of treated animals. A significant
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decrease of PT at almost all doses of PVP- and CT- AgNPs, as well as decrease of
aPTT at some doses suggest both intrinsic and extrinsic pathways may be involved to
cause prothrombotic effects in vivo. The results are in line with our earlier work with
iron oxide nanoparticles that showed shortened PT and aPTT [242]. Our study also
showed AgNPs are able to induce in vitro platelet aggregation and thereby
significantly decrease platelet count even at doses much lower than anticipated to
interact with systemic circulation after translocation of the highest instilled dose. These
data are also in agreement with previous studies which demonstrated that NPs induced
platelet aggregation in vitro [250, 259].
In the present study, the numbers of male and female mice used in each of the
studied group were equally distributed and their age was comparable (8 to 10 weeks).
However, we did not establish the stage of the estrous cycle of the experiments. The
latter has been reported to have an impact on vascular function and circulatory factors
[260]. Additional studies are required to clarify this point and to assess the AgNPs
distribution in various organs following pulmonary exposure.
To conclude, with this study, the influence of two distinct AgNPs (size 10 nm),
coating, concentration and two post exposure endpoints were comprehensively
assessed in an in vivo model. We demonstrated that the acute toxic effect on plasma
and heart after 1-day i.t instillation are dose- dependent and some of them persisted
even after 7-days post exposure. Overall, the highest concentration resulted in more
toxic effects for both PVP- and CT- AgNPs in heart and plasma, but the PVP- AgNPs
tended to induce a more significant effects at all doses compared with CT- AgNPs.
This suggests that application of AgNPs has to be carefully considered with respect to
dose and coating. In comparison, Ag+ ions revealed a dissimilar pattern of toxicity
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indicating that the in vivo effect of AgNPs may not only be attributed to release of Ag+
ions but also to the nanoparticulate form. The persistence of the cardiovascular effects
following single i.t. administration reported in the present study, and the fact that
occupational and consumer exposure to AgNPs are not time limited, additional studies
are required to evaluate the chronic effect of AgNPs exposure.
3.4 Study two: Coating and time-dependent effect and biodistribution of
pulmonary instilled silver nanoparticles in remote organs
3.4.1 Background
Previous studies have reported the translocation of AgNPs following various
routes of exposure including inhalation, instillation, oral and dermal [22, 105, 113,
166]. The directly administered (intravenous) AgNPs or translocated particles, either
in their ionic or nanoparticulate form, distributed to various organs and demonstrated
variable effects largely dependent on their size, shape, coating, dose and duration of
exposure [55, 73, 189]. Of all the potential routes, respiratory exposure of AgNPs is
a recent concern of the researchers as inhalation of AgNPs can occur at nanosilvermanufacturing industries during particle synthesis, handling of dry powders, as well
as during manufacturing of AgNPs containing products [88, 90, 99]. In this regard,
studies evaluating workplace exposure and health hazard have reported that
concentrations of AgNPs in the processes of manufacturing and integration of AgNPs
into various consumer products can reach up to 1.35 μg/m3 [90, 91]. Beside, use of
nanotechnology based consumer sprays containing AgNPs, can lead to the generation
of nanosized aerosols and the release of NPs near the human breathing zone [92, 93].
An occupational exposure limit of 0.19 μg/m3 for AgNPs, have been proposed by
Weldon BA et al. [97] based on subchronic rat inhalation toxicity study and taking in
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consideration the human equivalent concentration with kinetics. Inhaled particles of
~20 nm mainly deposits in the alveolar region and have shown to interact with lung
macrophages, epithelial cells and pulmonary surfactant [107, 167, 233]. Following
pulmonary exposure, there is evidence showing that AgNPs may translocate from the
lung to systemic circulation and eventually be deposited in remote organs causing
toxicity [167]. However, compared to number of studies evaluating pulmonary toxicity
to lung exposed AgNPs, there are much fewer investigations on the impact of
pulmonary exposure on extra-pulmonary targets particularly heart, liver, spleen,
kidney and brain [161, 168]. In this context, data from Holland et al. [174] showed
exacerbation of cardiac ischemic-reperfusion injury following single i.t. instillation of
20 nm AgNPs in rats with cardiovascular injury. Lee et al. [165] found that a short
term (14 days) nose only exposure of mice to 20 nm AgNPs at concentration of
1.91 × 107 particles/cm3 led to alterations in brain gene expression. Some studies also
demonstrated silver accumulation in olfactory bulb, kidney and spleen, following
pulmonary exposure [110, 167, 168]. However, yet a well understanding of the in vivo
distribution, accumulation and effect of pulmonary exposed AgNPs, in major organs
including liver, kidney, brain and spleen, is still lacking.
We recently studied the effect of pulmonary exposed 10 nm AgNPs, on
cardiovascular homeostasis and showed AgNPs can induce time and dose-dependent
cardiovascular effects including thrombosis, oxidative stress, inflammation,
coagulation and apoptosis [176]. In order to further investigate the effect of these NPs
on other major organs including liver, kidney, spleen and brain, we used the same type
of particles from the same source and assessed markers of inflammation, oxidative
stress, apoptosis and DNA damage. The latter effects were corelated with the
biodistribution of silver in the studied organs.
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3.4.2 Methods
Nanoparticles, silver acetate and vehicles
Suspensions of 10 nm polyvinylpyrrolidone (PVP) or citrate (CT) AgNPs
(BioPureTM) used in the present study were purchased from NanoComposix (San
Diego, CA, USA) and all the particles were thoroughly characterized in our recent
paper by techniques including transmission electron microscopy (TEM), size
distribution analysis and zeta potential measurement [118]. The individual particle size
of ~10 nm for both particle types were revealed in TEM. The size distribution analysis
revealed agglomeration of both PVP- and CT- AgNPs and homogeneous size
distribution of the agglomerates around 100 nm. The zeta potential for PVP- and CTAgNPs were -0.305 ± 0.09 mV and -36.25 ± 1.2, repsectively [176]. Silver acetate
(AgAc), as the source of Ag+ ions, was purchased from Sigma-Aldrich (#216674, St.
Louis, MO, USA). While 0.9% NaCl was used as control vehicle and diluent for PVPAgNPs and AgAc, 2 mM sodium citrate was used for CT- AgNPs group.
Animals and intratracheal (i.t.) administration of AgNPs
Both male and female BALB/C mice of age 8 -10 weeks (BW: 23 ± 2 g)
(Taconic Farms Inc., Germantown, NY, USA) were housed in light (12 hrs
light: 12 hrs dark cycle) and temperature-controlled (22 ± 1°C) rooms. They had free
access to commercial laboratory chow and were provided tap water ad libitum.
Pulmonary exposure was achieved by single i.t. instillation of 100 μL of either
PVP- or CT- AgNPs (5 mg/kg), or AgAc (8 mg/kg) or control vehicle by method
previously described [176, 228]. For each group a sample size of 6-8 mice were used
for histological, biomolecular and apoptotic studies. Another set of 5 animals for each
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treated group were used to study silver distribution in various organs. All the endpoints
were measured following 1 and 7-days of exposure. Immediately after the sacrifice,
the lung, liver, kidney, spleen and whole brain were harvested, homogenized and
supernatant collected for biochemical analysis. The total concentration of protein was
determined using bicinchoninic acid assay, as described earlier [176].
This study was reviewed and approved by the Institutional Review Board of
the United Arab Emirates University, College of Medicine and Health Sciences, and
experiments were performed in accordance with protocols approved by the
Institutional Animal Care and Research Advisory Committee.
Histology of tissues
Lungs, brain, kidney, spleen, liver and heart were excised immediately
following sacrifice, washed with ice-cold saline, dissected, casseted and fixed in 10%
neutral formalin for 24 hours. This was followed by dehydration in increasing
concentrations of ethanol, cleared with xylene and embedded with paraffin. Three- µm
sections of each tissue were prepared from paraffin blocks and stained with
hematoxylin and eosin (H & E) [228]. The stained sections were evaluated using light
microscopy by the histopathologist who participated in this project.
Measurement of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) in tissue
homogenates
TNF-α and IL-6 were measured using ELISA Kits (Duo Set, R & D systems,
Minneapolis, MN, USA).
Oxidative stress and lipid peroxidation evaluation: Detection of reduced glutathione
(GSH), total nitric oxide (NO) and 8 –isoprostane in tissue homogenates
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The concentration of GSH was measured using a commercially available kit
(Sigma-Aldrich Fine Chemicals, St Louis, MO, USA). The determination of NO was
performed with a total NO assay kit from R&D systems (Minneapolis, MN, USA)
which measures the more stable NO metabolites [261]. 8-isoprostane concentrations
were measured using ELISA Kit (Cayman Chemicals, Michigan, USA) [230].
Oxidative DNA damage evaluation by measurement of 8-hydroxy-2-deoxyguanosine
(8-OH-dG) in tissue homogenates
8-OH-dG was quantified using an ELISA kit (Cayman, Ann Arbor, MI, USA)
according to the manufacturer’s instruction [231].
In situ detection of apoptosis in tissues
Apoptotic cells were detected by terminal deoxynucleotide transferase
mediated dUTP nick end-labelling (TUNEL) assay, using a TACS® 2 TdT
diaminobenzidine (DAB) kit (Trevigen, Gaithersburg, MD, USA) according to
method previously described [176]. Briefly, 5 µm tissue sections were deparaffinized,
rehydrated and incubated with proteinase K. Following quenching, the tissue sections
were labelled with biotin labeled dUTP. The sections were then incubated with
horseradish peroxidase-conjugated streptavidin, washed, stained with DAB solution,
counterstained with methyl green and mounted. Negative and positive control of the
TUNEL assay were prepared according to the instruction of kit. Preparations were
observed and photographed using a light microscope. Cells with green nuclei after
TUNEL staining using methyl green were considered normal, whereas cells with
brown nuclei were considered apoptotic. Apoptotic (TUNEL positive) cells were
counted in at least ten areas per tissue section, in eight individual sections from each
animal, at 400X magnification.
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Measurement of total silver content
Total silver concentrations were determined in organs by inductively coupled
plasma mass spectrometer (ICP-MS), according to method previously described
[73]. Briefly, the heart, lungs, liver, spleen, kidneys, and brain (n = 4-5) were collected,
weighed and placed in acid washed tubes during necropsy. The organ tissues were then
digested in a microwave after addition of 3 ml HNO3 and 1 ml of H2O2. After cooling,
the digests were diluted by adding 3 M HCL. Then, the content of Ag (μg/g) in organs
was detected through ICP-MS (Optima 5300DV, America). Measurements were
carried out on 107Ag and 103Rh, as internal standard, by the method of external
calibration.
3.4.3 Results
Histopathological examination
Light microscopy analysis of the investigated tissue sections stained with H&E
is shown in Figure 13. In the lung, compared with their respective controls (A, B, C,
D), there was marked increase of inflammatory infiltrate in the sections of mice
instilled with either PVP- or CT- AgNPs (E, F, G, H), at both endpoints (1 and 7-days).
The intensity of infiltrate was higher after 7 days of exposure to 5 mg/kg PVP- and
CT- AgNPs. The inflammatory infiltrate consisted of neutrophil polymorphs,
macrophages, and lymphocytes. Likewise, compared with the control there was mild
peribronchial inflammatory cells infiltration consisting of neutrophil polymorphs and
lymphocytes, following 1 and 7-days of i.t. instillation of Ag+ ions (figure not shown).
Figure 13 also shows that there were unremarkable morphologic changes in liver,
kidney, spleen, brain and heart tissues of both control and treated groups.
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Figure 13: Representative light microscopy sections of lung, brain, kidney, spleen,
liver and heart tissues of control mice (A,B) and those treated with
polyvinylpyrrolidone (PVP) silver nanoparticles (AgNPs) at dose of 5 mg/kg , stained
with H&E (E,F) and of control mice (C,D) and those treated with citrate (CT) silver
nanoparticles (AgNPs) at dose 5 mg/kg, stained with H&E (G,H). All magnifications:
400X. The control group shows normal lung architecture and histology. PVP- and CTAgNPs treated group shows increased interstitial inflammatory cells following 1-day
and 7-days of intratracheal instillation in alveolar and bronchial walls. The
inflammatory infiltrate consists of neutrophil polymorphs (arrowhead), macrophages
(thick arrow) and lymphocytes (thin arrow).
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Effect of AgNPs and Ag+ on cytokines concentrations in homogenates
Concentrations of TNF-α and IL-6 are shown in Figure 14 and Figure 15. After
1-day exposure, the administered CT-AgNPs caused significant increase in the levels
of TNF-α in brain (P < 0.05) and liver (P < 0.001), comparted with their respective
control (Figure 14). The increase was statistically significant only in lung (P < 0.01)
for the PVP group. Similarly, Ag+ significantly augmented the level of TNF-α in
kidney (P < 0.05) and spleen (P < 0.001). Following 7-days of exposure, significant
increase was observed with, PVP- AgNPs in lung (P < 0.05) and Ag+ in kidney (P <
0.01).
In comparison with the control group, CT- AgNPs caused significant increase
of IL-6 in lung (P < 0.05), brain (P < 0.01) and liver (P < 0.001) following 1-day post
exposure (Figure 15). However, PVP- AgNPs showed significant increase only in lung
(P < 0.001). As for Ag+ significant increase was observed in lung (P < 0.05), kidney
(P < 0.01) and spleen (P < 0.01). Interestingly, following 7 days of i.t. instillation,
only Ag+ showed significant increase in kidney (P < 0.05).
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Figure 14: TNF-α concentrations in lung, brain, spleen, liver and kidney tissues
following 1-day and 7-days of intra-tracheal instillation of saline (control) or citrate 2
mM (control) or polyvinylpyrrolidine (PVP) or citrate (CT) silver nanoparticles
(AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each
group). Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.
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Figure 15: IL-6 concentrations in lung, brain, spleen, liver and kidney tissues following
1-day and 7-days of intra-tracheal instillation of saline (control) or citrate 2 mM
(control) or polyvinylpyrrolidine (PVP) or citrate (CT) silver nanoparticles (AgNPs)
or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each group).
Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.
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Effect of AgNPs and Ag+ ions on oxidative stress markers and lipid peroxidation in
tissue homogenates
The effects of PVP- and CT- AgNPs and Ag+ on the markers of oxidative stress
(GSH) and nitrosative stress (NO) and lipid peroxidation (8-isoprostane) in the lung,
liver, kidney, spleen, and brain are illustrated in Figures 16, 17 and 18. Following 1day exposure the concentration of GSH was significantly increased for CT- AgNPs in
lung (P < 0.001), brain (P < 0.05), kidney (P < 0.05) and spleen (P < 0.05) compared
to the control (Figure 16). The PVP- AgNPs showed significant increase in kidney (P
< 0.05) and liver (P < 0.001). Interestingly, a significant decrease was also observed
for Ag+ ions (P < 0.05). After 7-days, no significant changes were observed in either
PVP- or CT- AgNPs group. However, Ag+ showed significant increase of GSH in lung
(P < 0.001) and decrease in spleen (P < 0.001) following 7-days of exposure.
As shown in Figure 17, post 1-day instillation, total NO was significantly
increased for the CT- AgNPs in lung (P < 0.01), brain (P < 0.001) and kidney (P <
0.01), compared to the control. The increase was significant only in liver (P < 0.05)
for the PVP- AgNPs. For the Ag+ treated animals significant increase was achieved in
lung (P < 0.05) and kidney (P < 0.01). At 7-days, significant increase was observed
with only CT- AgNPs in kidney (P < 0.01) and Ag+ in spleen (P < 0.01).
8-isoprostane was measured as marker of lipid peroxidation and the results are
shown in Figure 18. Following 1-day post exposure, significant increase was observed
in lung (P < 0.01) and brain (P < 0.05) for CT- AgNPs, in lung(P < 0.001) and liver
(P < 0.01) for PVP-AgNPs, and in spleen (P < 0.01) and liver(P < 0.05) for Ag+,
compared to their respective controls. No significant changes were observed following
7-days of instillation.

95

Figure 16: Reduced glutathione (GSH) levels in lung, brain, spleen, liver and kidney
tissues following 1-day and 7-days of intra-tracheal instillation of saline (control) or
citrate 2 mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver
nanoparticles(AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 68 in each group). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.
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Figure 17: Total NO levels in lung, brain, spleen, liver and kidney tissues following 1day and 7-days of intra-tracheal instillation of saline (control) or citrate 2 mM (control)
or polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles (AgNPs) or silver
acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each group). Statistical
analysis by one-way ANOVA followed by Holm-Sidak’s multiple comparison test.
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Figure 18: 8-isoprostane levels in lung, brain, spleen, liver and kidney tissues
following 1-day and 7-days of intra-tracheal instillation of saline (control) or citrate 2
mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles
(AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 6-8 in each
group). Statistical analysis by one-way ANOVA followed by Holm-Sidak’s multiple
comparison test.
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Effect of AgNPs and Ag+ ions on 8-OH-dG concentrations in tissue homogenates
Figure 19 shows the concentration of 8-OH-dG in lung, liver, kidney, spleen,
and brain following 1 and 7-days of i.t. instillation of either AgNPs or Ag+. Following
1-day exposure, while the concentration of 8-OH-dG significantly increased for CTAgNPs in lung (P < 0.01) and brain (P < 0.05), for PVP- AgNPs the increase was
significant in lung (P < 0.001) and liver (P < 0.05) compared to their respective control.
A significant increase was also observed with Ag+ in lung (P < 0.05) and liver (P <
0.001). No effect on 8-OH-dG was observed following 7-days of i.t. instillation of
either AgNPs or Ag+.
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Figure 19: 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels in lung, brain, spleen, liver
and kidney tissues following 1-day and 7-days of intra-tracheal instillation of saline
(control) or citrate 2 mM (control) or polyvinylpyrrolidone (PVP) or citrate (CT) silver
nanoparticles (AgNPs) or silver acetate (AgAc) in mice. Data are mean ± SEM (n = 68 in each group). Statistical analysis by one-way ANOVA followed by HolmSidak’s multiple comparison test.
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Measurement of apoptosis
Figure 20 represents percentage of tunel positive cells with the representative
images for all particles in lung, brain and liver. Following 1-day post exposure,
compared to the respective controls, a significant increase was observed with CT AgNPs in lung (P < 0.001) and brain (P < 0.001), and PVP- AgNPs showed significant
increase in lung (P < 0.001) and liver (P < 0.001). Ag+ ions showed significant increase
in liver (P < 0.001). No significant changes were observed post 7-days of instillation.
No apoptosis has been detected in the kidney or spleen for either particles at any time
point.
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Figure 20: Estimation of apoptotic cells by an in situ TUNEL assay in tissue
sections and their representative images, following 1-day and 7-days of intratracheal instillation of saline (control) or citrate 2 mM (control) or
polyvinylpyrrolidone (PVP) or citrate (CT) silver nanoparticles (AgNPs) or
silver acetate (AgAc) in mice. The inset images are represented by yellow
arrows. Counts of apoptotic cells were made in the sections (n=7-8 per group)
at a final magnification of X200 and the average of apoptotic cell numbers in
per group were calculated.
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Figure 20: Estimation of apoptotic cells by an in situ TUNEL assay in tissue sections
and their representative images, following 1-day and 7-days of intra-tracheal
instillation of saline (control) or citrate 2 mM (control) or polyvinylpyrrolidone (PVP)
or citrate (CT) silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice. The
inset images are represented by yellow arrows. Counts of apoptotic cells were made in
the sections (n=7-8 per group) at a final magnification of X200 and the average of
apoptotic cell numbers in per group were calculated (cont’d).
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Figure 20: Estimation of apoptotic cells by an in situ TUNEL assay in tissue sections
and their representative images, following 1-day and 7-days of intra-tracheal
instillation of saline (control) or citrate 2 mM (control) or polyvinylpyrrolidone (PVP)
or citrate (CT) silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice. The
inset images are represented by yellow arrows. Counts of apoptotic cells were made in
the sections (n=7-8 per group) at a final magnification of X200 and the average of
apoptotic cell numbers in per group were calculated (cont’d).
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Measurement of total Ag content in tissues
Table 8 shows the distribution of Ag in lung, heart, liver, kidney, spleen and
brain. Following 1-day of i.t. instillation, highest concentration of Ag was detected in
spleen, liver, lung, heart, kidney and brain. For CT-AgNPs, the highest concentration
was detected in lung followed by spleen, liver, heart, kidney and brain. For Ag+ ions
the highest amount was detected in liver followed by lung, spleen, heart, kidney and
brain. Post 7-days instillation, the amount of silver detected was reduced for all the
particles used. However, Ag content was more some organs for the AgAc treated group
compared with PVP- or CT- AgNPs treated group.
Table 8: Concentrations of Ag (µg/g) in lung, heart, brain, kidney, spleen and liver
following 1-day and 7-days of intra-tracheal instillation of polyvinylpyrrolidine
(PVP) or citrate (CT) silver nanoparticles (AgNPs) or silver acetate (AgAc) in mice.
Organs

Amount of Silver (µg/g of tissue)
1 day

7 days

PVPAgNPs

CTAgNPs

AgAc

PVPAGNPs

CTAgNPs

AgAc

Lung

0.10 ± 0.02

0.11 ±
0.03

0.72 ±
0.25

0.19 ± 0.1

0.06 ±
0.01

0.4 ± 0.09

Heart

0.04 ± 0.01

0.01 ±
0.01

0.15 ±
0.06

0.01 ± 0.0

0.0 ± 0.0

0.08 ±
0.07

Brain

0.02 ± 0.0

0.02 ± 0.0

0.07 ± 0.1

0.03 ± 0.0

0.02 ± 0.0

0.08 ± 0.4

Kidney

0.02 ± 0.01

0.01 ± 0.0

0.13 ±
0.04

0.0 ± 0.0

0.0 ± 0.0

0.28 ±
0.27

Spleen

0.18 ± 0.08

0.05 ±
0.01

0.49 ±
0.16

0.01 ±
0.01

0.0 ± 0.0

0.25 ±
0.24

Liver

0.13 ± 0.05

0.05 ±
0.02

0.9 ± 0.26

0.01 ±
0.01

0.0 ±0.0

0.35 ± 0.3

Data are mean ± SEM (n = 4-6 in each group).
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3.4.4 Discussions
Silver is one of the most frequently used nanomaterials for consumer products
and respiratory exposure to AgNPs containing aerosolized products provides a
potential route of interaction with human health. The effects to inhaled or instilled
AgNPs have been discussed in several studies though there is discrepancies in their
results. For instance, a 28-day inhalation toxicity study on rats showed no significant
changes in the hematology and blood biochemistry in either the male or female rats
following 11-14 nm AgNPs at concentration of 1.73 x 104/cm3, 1.27 x 105/cm3 and
1.32 x 106 particles/cm3 [161]. Likewise Hyun et al. [164] exposed rats to 12-15 nm
AgNPs for similar duration and doses and showed no remarkable histopathological
changes in the nasal cavity and lung of the exposed group compared to the control
group. On the other hand, 14-days and 90-days exposure studies to 20 nm and 18 nm
AgNPs respectively, demonstrated dose-dependent pulmonary inflammation,
alterations in pulmonary functions and brain gene expression [163, 165].
Several studies not only reported the occurrence of lung inflammation and
oxidative stress but also particle translocation and accumulation in secondary organs,
such as the liver, following i.t. instillation or inhalation AgNPs [110, 161, 167, 168,
171]. In addition, few other researches also demonstrated the biodistribution of
pulmonary exposed AgNPs to kidney, spleen, brain, olfactory bulb and placenta [110,
167-169]. However, the effects of AgNPs on these organs have not been clearly
identified. Moreover, we have recently showed that pulmonary exposure to AgNPs
induce time and dose-dependent cardiovascular effects [176]. The data in the latter
study revealed significant effect of AgNPs on proinflammatory markers, oxidative
stress, DNA damage and apoptosis in heart [176]. Consequently, we thought it was
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important to assess the pathophysiological mechanisms and biodistribution of
pulmonary exposure to AgNPs in other distant major organs including liver, brain,
spleen and kidney. Thus, in the present study, we did not assess the impact of AgNPs
on cardiac inflammation, oxidative stress and apoptosis because this has been recently
reported by our group [176]. However, we have included the heart in the study related
to the biodistribution of AgNPs.
The particles, route of administration (i.t.), and time points (1 day and 7-days)
were chosen to be the same as that of our recent paper where we investigated the effect
of i.t. instilled PVP- and CT- AgNPs in heart and plasma [176]. In the latter study, we
used 3 doses (0.05, 0.5 and 5 mg/kg BW) and observed the effects in cardiovascular
system were more prominent and significant at the dose of 5 mg/kg AgNPs and
equivalent dose of 8 mg/kg AgAc. Hence, we chose the same dose to evaluate the
pathophysiological responses in other major organs for the present study. As far as we
are aware, no study has investigated systematically the biodistribution and the
inflammation (TNF-α and IL-6), oxidative stress (GSH, total NO and 8-isoprostane),
and DNA damage (8-OH-dG and TUNEL assay) in the lung and important secondary
organs including liver, kidney, spleen, and brain.
Our histological data show that exposure to PVP- or CT- AgNPs or Ag+ ions
triggered lung inflammation substantiated by interstitial infiltration of inflammatory
cells consisting of neutrophils, lymphocytes and macrophages. All the observed effects
persisted after 7-days of instillation and this corroborates the results of Silva et al. who
demonstrated persistence of inflammatory infiltrates at 7-days post exposure of either
PVP- or CT- AgNPs [173]. Interesting to note that, no significant difference were
observed in the intensity of inflammation between the different coatings and different
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particle used, AgNPs or Ag+ ions, which suggests that the extra-pulmonary effects
observed herein by subsequent assays could be attributed to either the AgNPs
themselves or inflammation induced or due to the release of Ag+ ions [234].
The present data further revealed that pulmonary exposure to AgNPs induced
a significant augmentation in the concentrations of two of the major pro-inflammatory
cytokines, TNF-α and IL-6. While PVP- AgNPs caused significant increase of TNF-α
in lung, CT- AgNPs showed increase in brain and liver. As for IL-6, CT- AgNPs
induced significant increase in lung, brain and liver, while PVP-AgNPs showed the
increase only in lung. The Ag+ ions on the other hand induced these effects in kidney
and spleen. None of these effects persisted after 7-days except for TNF-α in lung
caused by PVP-AgNPs, and TNF-α and IL-6 in kidneys caused by Ag+ ions.
Interestingly, a significant increase of TNF-α and IL-6 have also been observed in
heart post 1-day exposure to PVP- and CT- AgNPs in our recent study [176].
Oxidative stress, characterized by the formation of a wide range of reactive oxygen
species, is a key pathological process in a variety of disease conditions affecting
various organs such as the lung, heart, kidney and liver. It subsequently results in
DNA, protein, and lipid damage leading to cellular dysfunction and death [241].
Beside measuring markers of inflammation, we also provide evidence that both coating
AgNPs cause significant increase in oxidative stress. While CT- AgNPs showed
increase in GSH in lung, brain, kidney and spleen, PVP- AgNPs increased GSH in
kidney and liver and Ag+ ions in spleen, following 1-day exposure. An increase of total
NO was also observed with CT- AgNPS in lung, brain and kidney; PVP- AgNPs in
liver; and Ag ions in lung and kidney. These effects however declined 7-days post
exposure except for effect CT- AgNPs in kidney. Our present data also show that
exposure to AgNPs induced a significant increase of 8-isoprostane, a marker of lipid
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peroxidation, in the lungs and brain (for CT coating), in lung and liver (for PVPcoating) and in spleen and liver for Ag+ ions. Augmentation of oxidative stress markers
including GSH, total antioxidants and 8-isoprostane were also observed in heart of
PVP- and CT- AgNPs exposed mice [176]. This derangement of oxidative biomarkers
is in line with other previous reports and indicate that either parenteral or oral
administration of AgNPs promoted inflammatory reactions and oxidative stress in
lung, liver, and brain [159, 187, 193, 207]. Even though the release of markers
investigated in this study varied between the particle type used and the investigated
organs, at least one or more than one marker of inflammation and oxidative stress
augmented in each studied organ, showing the occurrence of inflammation and
oxidative stress after i.t. instillation of AgNPs.or Ag+ ions.
The effect of AgNPs on DNA damage in the remote organs following
pulmonary exposure to AgNPs have never been reported so far in vivo. In the present
study, we evaluated DNA damage in lung, brain, kidney, spleen and liver by measuring
8-OH-dG levels and apoptosis by TUNEL assay. 8-OH-dG is one of the predominant
forms of free radical induced oxidative lesions, and has therefore been widely used as
a biomarker for oxidative damage to DNA [244]. Increase in 8-OH-dG levels was
reported in liver, brain, and kidney following administration of TiO2, gold or iron oxide
NPs [245-247]. Our present data showed that post 1-day exposure, CT-AgNPs
significantly increased 8-OH-dG in lung and brain, PVP- AgNPs and Ag+ ions in lung
and liver. TUNEL assay is one of the most widely used methods for detecting apoptotic
cells in situ and is based on the ability of the enzyme terminal deoxynucleotidyl
transferase to incorporate labelled dUTP into free 3′-hydroxyl termini generated by the
fragmentation of DNA [248]. Apoptosis is a distinctive mode of programmed cell
death and occurs as a defense mechanism when cells are damaged beyond repair,
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particularly when disease or toxicant mediated damage affects cellular DNA, and
cellular repair mechanisms are unable to deal with the injury [262]. Our data show
significant increase in tunel positive cells in lung, brain and liver with CT- AgNPs in
lung and brain; PVP- AgNPs in lung and liver and with Ag+ ions in lung and liver
following 1 day after instillation and the results are relatable to our finding of 8-OHdG level. Moreover, our recent paper evaluating the cardiovascular effect also showed
significant increase in 8-OH-dG in heart and tunel positive cardiomyocytes following
1-day post instillation of PVP- and CT- AgNPs at concentration of 5 mg/kg [176].
Overall, pulmonary exposed PVP- and CT- AgNPs induced pro-inflammatory cells
and oxidative stress in major organs including lung, heart, liver, kidney and brain,
evidenced by an increase of TNF-α, IL-6, GSH, NO and 8-isoprostane, and caused
DNA damage, thereby reinforcing the previously established mechanisms of DNA
damage caused by reactive oxygen species and eventually resulting in cellular
dysfunction and apoptosis [238, 249].
Distribution of silver in the different organs, 1 day and 7 days after i.t. exposure
to CT- and PVP-coated AgNPs and Ag+ ions were evaluated using ICP-MS. Our
present data revealed accumulation of silver, post 1 day of i.t. instillation, in all the
organs examined with the highest in lung, spleen and liver, similar to previous
respiratory exposed AgNPs studies [110, 161, 167, 169]. Interestingly, particles
administered intravenously or intraperitoneally also showed liver, spleen and kidney
to be the major target organs for Ag accumulation [40, 73, 112]. Ag was also detected
in organs following 7-days post exposure to Ag+ ions, with some of the organs showing
more than that treated with AgNPs, Furthermore, the findings in our study suggest that
lung exposed 10 nm AgNPs were translocated either in nanoparticulate or ionic form

110
and distributed to the different tissues during the 1st day as well as 7th day post
exposure.
To conclude, with this study, the influence of two distinct AgNPs (size 10 nm),
coating, and two post exposure endpoints (1 and 7 days) were comprehensively
assessed in an in vivo model. We demonstrated acute toxic effect of AgNPs as well as
Ag+ ions at the site of administration i.e. lung, as well as in the remote organs including
brain, kidney, spleen and liver. It is of utmost significance that particle deposited in
lung are not only ably to translocate and accumulate in various organs, but also induce
pathophysiological effect in the same. More importantly these particles were able
induce DNA damage and apoptosis in brain. In this regard, Lee et al. [165] also
demonstrated alteration in brain gene expression caused by short term pulmonary
exposure of 20 nm AgNPs, in mice. These results suggest that application of AgNPs
has to be carefully considered with respect to size, dose, coating and duration of
exposure. It is also important to highlight that Ag+ ions revealed a dissimilar pattern
of toxicity emphasizing the fact that, the in vivo effect of AgNPs observed, may not
only be attributed to release of Ag+ ions but also to the nanoparticulate form. The
persistence of these pathophysiological effects following single i.t. administration
reported in the present study, and the fact that occupational and consumer exposure to
AgNPs are not time limited, additional studies are warranted to evaluate the chronic
effect of AgNPs exposure.
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3.5 Study three: The in vitro effect of polyvinylpyrrolidone and citrate coated
silver nanoparticles on erythrocytic oxidative damage and eryptosis
3.5.1 Background
Extensive increase in the use of AgNPs has raised serious concerns about their
potential adverse effects and toxicity on human health [24, 25]. There are several
mechanisms through which AgNPs can enter the human body and interact with blood
components, either directly, or indirectly. The respiratory system provides a major
portal for AgNPs used extensively in healthcare and hygiene sprays [263]. In this
context, several animal and human studies have demonstrated significant alveolarcapillary translocation of inhaled nanoparticles via endocytocis or transcytosis [263265]. In addition, penetration into hair follicles of NPs has been previously reported
[266]. In fact, close contact with AgNPs used as coatings in surgical dressings may
allow AgNPs to penetrate the skin barrier and enter the capillaries [263]. AgNPs are
also used widely as food preservatives and water disinfectants [267]. Hence, the
gastrointestinal system provides another route for AgNPs entry to human body [263].
Other potential route of AgNPs in case of biomedical applications includes parenteral
administration, where AgNPs are able to directly interact with blood components
[268], including erythrocytes and may potentially induce pathophysiological effects.
Previous studies using diesel exhaust particle (DEP), silica nanoparticles
(SiNPs) and lead nanoparticles (PbNPs) have demonstrated significant hemolysis and
oxidative stress on human, rat and mouse erythrocytes [269, 270]. In addition, studies
using human erythrocytes have investigated the effects of AgNPs on hemolysis,
morphology and their uptake [139, 141]. Nevertheless, the mechanism underlying the
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pathophysiological effects of AgNPs on erythrocytes physiology is not fully
understood.
Several physiochemical properties determine the toxicity of AgNPs including
their size, shape and surface chemistry [74]. In addition, coating has been reported to
play an important role in NPs toxicity. In this context, in vivo studies have reported
that polyvinylpyrrolidone (PVP) and citrate (CT) coated AgNPs induce tissue specific
toxicity and aggravate cardiac ischemic reperfusion injury [73, 175]. Moreover, a
previous in vitro study has shown that PVP- and CT- AgNPs induce toxicity in
J774A.1 macrophage and HT29 epithelial cells [47]. Also, Huang et al [145] have
investigated the hemolytic effect of PVP- and CT- AgNPs on human erythrocytes.
However, to our knowledge, no study has comprehensively evaluated the effect of
PVP- and CT- AgNPs on hemolysis, oxidative stress, calcium homeostasis and
eryptosis. Hence, the aim of our study was to investigate the mechanism underlying
the effect of PVP- and CT- AgNPs, at various concentrations (2.5, 10 and 40 µg/ml),
on hemolysis, uptake of AgNPs by erythrocytes, oxidative stress, intracellular calcium,
annexin V, caspase 3 and calpain.
3.5.2 Materials and Methods
Particles
Suspensions of silver nanoparticles of 10 nm (BioPureTM), coated with either
PVP or CT were purchased from NanoComposix (San Diego, CA, USA). The
provided stock concentrations were 1.0 mg/ml with endotoxin level <5 EU/ml and
silver purity of 99.99%. The zeta potential of PVP- and CT- AgNPs were -26 mV and
-33 mV, respectively, and the surface areas were 53.5 m2/g and 59.0 m2/g, respectively.
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The pH of both the suspensions was 7.4. The suspending solvents of PVP- and CTAgNPs were 0.9% NaCl and 2.0 mM sodium citrate, respectively. To minimize
aggregation, the stock particle suspensions were always sonicated for 15 min and
vortexed for 30 sec before their dilution, or before incubation with erythrocytes.
Transmission electron microscopy (TEM) of AgNPs
We analyzed the nanoparticle suspension used in our study by TEM. The
suspensions were primarily subjected to sonication at room temperature for 15 min
prior to processing for TEM. A drop of PVP- and CT- AgNPs suspensions were
deposited on a 200 mesh Formvar/Carbon coated copper grid and allowed to dry for 1
hr at room temperature. Then the grids were examined and photographed at different
magnifications using FEI Tecnai Biotwin Spirit G2 TEM (FEI, Eindhovon,
Netherlands).
Animal handling and blood collection
Balb/C mice were housed in light (12 hrs light:12 hrs dark cycle) and
temperature controlled (22 ± 1°C) rooms. They had free access to water and standard
pallet diet ad libitum. All experimental procedures were in accordance with protocols
of the Institutional Animal Care and Research Advisory Committee and the project
approved by Institutional Review Board of United Arab Emirates University.
Animals were anesthetized intraperitonially with sodium pentobarbital 30
mg/kg, and then blood was drawn from the inferior vena-cava with syringe prewetted
with 4% sodium citrate and collected in ethylenediamine tetraacetic acid (4%)
containing tubes. The blood sample was then processed according to the type of
experiment conducted.
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Preparation of erythrocytes
The method for preparation of erythrocytes used in the present study has been
previously described [271, 272]. Briefly, collected mouse blood was mixed by gentle
inversion of tube and centrifuged at 1200 g for 15 min. The plasma supernatant was
discarded, and the erythrocytes were washed 4 times by suspending them in 0.9% NaCl
followed by centrifugation at 1200 g for 10 mins. The final suspension consisted of
5% by volume of erythrocyte in saline. Flat bottom well plates were used to incubate
840 µl of erythrocyte with 160 µl of PVP- and CT- coated AgNP suspensions (2.5, 10
and 40 µg/ml). Negative control consisted of 0.9% NaCl and 2 mM Citrate
respectively. Positive control consisted of 0.1% Triton X 100. The plates were
incubated for 4 h at room temperature under shaded light, shaking gently on an orbital
plate shaker. After incubation the samples were transferred to 1.5 ml eppendorf tube
and were centrifuged at 1200 g for 5 min. The resulting supernatant was collected for
hemolysis assay, annexin V and oxidative markers assays. The deposited erythrocytes
were fixed with Karnovsky’s fixative (2% paraformaldehyde and 2.5% glutaraldehyde
in 0.1 M phosphate buffer at 7.2 pH) for TEM.
Hemolysis assay
The hemolysis assay was performed according to previously reported
technique [269, 273]. Briefly, erythrocytes incubated with PVP- and CT- AgNPs was
centrifuged as described above. After that, 90 µl of the supernatant was added in a 96
well

plate

and

the

amount

of

hemoglobin

released

was

determined

spectrophotometrically at a wavelength of 540 nm. The percent hemolysis was
calculated using the linear equation y = mx + c where %hemolysis (x) = [(sample
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optical density (y) – negative control optical density (c))/ (positive control optical
density – negative control optical density) (m)] * 100 [271, 272].
Erythrocyte analysis by TEM
Fixed cells were processed according to method described previously [269].
Briefly, the cells were washed with 0.1 M phosphate buffer and for 1 hr at room
temperature on rotamixer and post fixed with 1% osmium tetraoxide in 100 mM
cacodylate buffer. After that cells were dehydrated in a series of graded ethanol
concentration, infiltrated with Agar 100 epoxy resin, embedded into resin filled molds
and polymerized at 65°C for 24 hrs. Blocks were trimmed and ultrathin sections were
obtained by an ultra-microtome (Leica, Mikrosysteme GmbH, Wien, Austria).
Ultrathin sections were collected on 200 mesh Cu grids and were contrasted with
uranyl acetate and followed by lead citrate double stain. The grids were examined and
photographed at variable magnification by TEM [269, 274].
Measurements of oxidative stress markers
Supernatants were collected after incubation of erythrocytes with PVP- and
CT- AgNP (2.5, 10 and 40 µg/ml) by the process described above and was subjected
to oxidative stress marker assay. The erythrocytes treated with 0.9% NaCl and 2 mM
citrate were taken as control. Erythrocyte malondialdehyde (MDA) was quantified
colorimetrically following its controlled reaction with thiobarbituric acid [275] with a
commercially available kit (Cayman chemicals, Ann Abror, MI, USA). Reduced
glutathione (GSH) concentration (Sigma Chemicals, St Loius, MO, USA) and catalase
(CAT) activity (Activity kit, Cayman chemicals, Ann Abror, MI, USA) were analyzed
spectrophotometrically according to methods described by the manufacturers.
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Measurement of intracellular calcium
Intracellular Ca2+ was measured in incubated medium of erythrocytes treated
with either vehicle or various concentrations of PVP- and CT- AgNPs according to a
previously described technique [276]. Briefly, erythrocytes were washed with saline
(0.9% NaCl) four times followed by centrifugation for 10 min at 1200 g. The
erythrocytes were then resuspended in 1 mM Ringers solution. The final suspension
consisted of 0.5% hematocrit of erythrocyte in 1 mM Ringers solution. The cells were
then incubated in a flat bottom plate with the AgNPs at 37°C for 4 hrs. After that the
incubated cell suspensions were collected in eppendorf tube and centrifuged for 5 min
at 1200 g. The supernatant was discarded, and the cells resuspended in 5 mM Ringers
solution to which 5 μl of Fura 2AM (Calbiochem; La Jolla, CA, USA) was added and
incubated for 15 min at 37°C in dark on a shaker. After that, the cell suspensions were
centrifuged at 1200 g for 5 min. The Fura 2AM loaded erythrocytes were resuspended
in 1 mM Ringers solution and incubated for 30 min at 37°C in dark on a shaker. Finally
Ca2+ - dependent fluorescence intensity was then monitored with a fluorometer (model
SFM 25, Kontron; Zurich, Switzerland) set at 340 nm excitation and 510 nm emission
[277].
Assessment of Annexin V
Annexin V bound to exposed phosphatidylserine was measured in incubated
medium of erythrocytes using mouse ANXA5 ELISA kit according to manufacturer’s
instruction (Elabscience, Texas, USA).
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Caspase 3 analysis
The activity of caspase 3 was determined in incubated medium of erythrocytes
using a caspase 3 activity fluorometric assay kit according to manufacturer’s
instruction (BD Biosciencences, San Jose, CA)
Moreover, caspase 3 expression was analysed by Western blot analysis
according to previously described technique [278]. Freshly isolated erythrocytes that
were incubated with either vehicle or various concentrations of PVP- or CT- AgNPs,
were washed twice in PBS and lysed in 250 µl of radioimmunoprecipitation assay
(RIPA) buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitor. Insolubilized
material was removed by centrifugation at 14000 g for 15 min. The supernatants were
immediately removed and used for protein estimation using a Pierce bicinchoninic acid
protein assay kit (Thermo Scientific, Waltham, MA, USA). A 100 µg of protein/ lane
was electrophoretically resolved by 12% sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene difluoride
membranes. The immunoblots were blocked for 2 hrs, with 5% nonfat dry milk in
1X Tris-buffered saline containing Tween 20 (1%, v/v) (TBST) and subsequently
incubated overnight at 4°C with rabbit polyclonal caspase-3 antibody (1:1000 dilution,
Cell Signalling Technology, Danvers, MA, USA) in 5% w/v nonfat dry milk. The blots
were then incubated with goat anti-rabbit IgG horseradish peroxidase (HRP)
conjugated secondary antibody (1:5000 dilution, Abcam), for 2 hrs, at room
temperature, and developed using Pierce enhanced chemiluminescent plus Western
blotting substrate Kit (Thermo Scientific). The densitometric analysis of the protein
bands was performed for caspase-3 with Typhoon FLA 9500 (GE Healthcare Bio-
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Sciences AB, Uppsala, Sweden). Blots were then re-probed with mouse monoclonal
β-actin HRP conjugated antibody (1:1000 dilution, Santa Cruz Biotechnology, Dallas,
Texas, U.S.A) and used as a loading control.
Measurement of calpain activity
The activated calpain in cytosol of incubated erythrocytes was flurometrically
determined using a calpain activity assay kit according to manufacturer’s instruction
(Genway Biotech, San Diego, USA).
Statistics
All statistical analyses were performed with GraphPad Prism Software version
7 (San Diego, CA, USA) and the data and figures were reported as mean ± SEM.
Comparisons between groups were performed by one-way analysis variance
(ANOVA) followed by Dunnett’s multiple range test. P-values < 0.05 were considered
as significant.
3.5.3 Results
Characterization of PVP- and CT- AgNPs
The morphology and particle size of PVP- and CT- AgNPs were determined
by TEM are shown in Figure 21. TEM analysis of PVP- and CT- AgNPs revealed
homogenous particle size of approximately 10 nm in diameter and this corroborates
the size provided by the manufacturer. Both types of AgNPs were spherical in shape.
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Figure 21: Transmission electron microscope analysis of polyvinylpyrrolidone (A) or
citrate (B) coated silver nanoparticles.

Effect of AgNPs on erythrocyte hemolysis
Figure 22 shows the hemolytic effect of AgNPs on erythrocytes. Incubation of
erythrocytes with AgNPs caused a dose-dependent hemolysis. The effects were
significant at concentrations of 10 µg/ml (P < 0.001) and 40 µg/ml (P < 0.001) for
PVP- AgNPs and at a concentration of 40 µg/ml (P < 0.001) for CT- AgNPs compared
with their respective controls. The degree of hemolysis observed at concentration of
2.5, 10 and 40 µg/ml for PVP- AgNPs were 0.99%, 3.96% and 16.34% and those
observed for CT- AgNPs were 2.43%, 2.67% and 16.67% respectively.
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Figure 22: Hemolytic effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver
nanoparticles (AgNPs) on mouse erythrocytes.

Erythrocyte analysis by EM
TEM images of erythrocytes incubated with PVP- and CT- AgNPs at
concentration of 2.5, 10 and 40 µg/ml are shown in Figure 23. Both types of AgNPs
were found to be taken up by erythrocytes at all tested concentrations. In the
erythrocytes the AgNPs were located both within as well as on the margins.
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Figure 23: Transmission electron microscope (TEM) analysis of erythrocytes after in
vitro incubation with saline (control, A), polyvinylpyrrolidone (PVP) silver
nanoparticles (AgNPs) 2.5, 10, 40 µg/ml (B, C, D respectively), 2 mM citrate (control,
E) or citrate (CT) coated AgNPs 2.5, 10, 40 µg/ml (F, G, H respectively). AgNPs are
localized within (thin arrows) as well as on the margins (thick arrows) of the
erythrocytes.

Effect of AgNPs on concentrations of MDA and GSH and CAT activity
Concentrations of MDA, GSH and measurement of CAT activity are shown in
Figure 24. MDA was used to assess the susceptibility of erythrocytes lipid
peroxidation in vitro. Compared with their respective controls, the MDA concentration
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was dose-dependently increased by the incubation of erythrocytes with various
concentrations of PVP- and CT- AgNPs (Fig. 24 A). However, the level of significance
was only achieved at highest tested concentration, i.e. 40 µg/ml (P < 0.001) for both
PVP-and CT- AgNPs. Figure 24 B shows the effect of AgNPs on concentration of
GSH. Compared with control, the concentration of GSH was significantly decreased.
The level of significance was achieved at all studied concentrations (P < 0.001) for
both PVP- and CT- AgNPs. Likewise, compared with their respective controls, there
was a significant decrease of catalase activity in erythrocytes incubated with PVP and
CT- AgNPs at all tested concentrations (P < 0.001) as shown in Figure 24 C.
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Figure 24: Effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver nanoparticles
(AgNPs) on concentration of malonaldialdehyde (MDA, A), reduced glutathione
(GSH, B) and catalase activity (C) measured in the incubation medium of erythrocytes.
Data are mean± SEM (n=8 in each group). Statistical analysis by one-way anova
followed by Dunnett’s multiple range test.
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Effect of AgNPs on intracellular calcium
Figure 25 illustrates the effect of various concentrations of PVP- and CTAgNPs on cytosolic calcium concentration from Fluro3 fluorescence. The incubation
of erythrocytes with AgNPs caused a dose-dependent increase in cytosolic calcium
concentration compared with control. While the level of significance was achieved at
10 and 40 µg/ml (P < 0.001) for PVP- AgNPs, the CT- AgNPs showed increased
cytosolic calcium concentration at all tested dose, i.e. 2.5, 10, and 40 µg/ml (P <
0.001).
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Figure 25: Effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver nanoparticles
(AgNPs) on intracellular calcium concentration measured in incubated erythrocytes.
Data are mean± SEM (n=8 in each group). Statistical analysis by one-way anova
followed by Dunnett’s multiple range test.
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Effect of AgNPs on annexin V-binding
Exposure of phosphatidylserine at the cell surface was estimated from bound
annexin V. Incubation of erythrocyte with PVP- and CT- AgNPs triggered annexin V
binding as shown in Figure 26. The effect was significant at concentration of 2.5 µg/ml
(P < 0.05), 10 µg/ml (P < 0.001) and 40 µg/ml (P < 0.001) of PVP- AgNPs. The effect
of CT- AgNPs was also significant at all concentrations used, i.e. 2.5, 10 and 40 µg/ml
(P < 0.001).
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Figure 26: Effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver nanoparticles
(AgNPs) on the concentration of bound Annexin V in the incubation medium of
erythrocytes. Data are mean± SEM (n=8 in each group). Statistical analysis by oneway anova followed by Dunnett’s multiple range test.
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Effect of AgNPs on caspase 3 activity and expression
The assessments of caspase 3 activity and expression in erythrocytes following
exposure to various concentrations of PVP- or CT- AgNPs are represented in Figure
27. Overall, there was no effect of both PVP- and CT- AgNPs on caspase activity in
incubated erythrocytes. Compared with the control group, only CT- AgNPs showed a
significant increase at a dose 10 µg/ml (P < 0.05). Likewise, compared with the control
group, the western blot analysis showed no statistically significant effect of various
concentrations of PVP- or CT- AgNPs on total caspase 3 expression in erythrocytes.

Figure 27: Effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver nanoparticles
(AgNPs) on erythrocyte caspase 3 activity (A) and caspase 3 expression assessed by
western blotting (B). Data are mean± SEM (n=7-8 in each group). Statistical analysis
by one-way anova followed by Dunnett’s multiple range test.

Effect of AgNPs on calpain activity
Detection of activated calpain in cytosol upon incubation of erythrocytes with
PVP- and CT- AgNPs is shown in Figure 28. Compared with the control, the
incubation of erythrocytes with PVP- AgNPs caused a significant increase in calpain
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activity at dose 40 µg/ml (P < 0.01), and incubation with CT- AgNPs caused a
significant increase in calpain activity at all concentrations used, i.e. 2.5, 10 and 40
µg/ml (P < 0.001).
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Figure 28: Effect of polyvinylpyrrolidone (PVP) and citrate (CT) silver nanoparticles
(AgNPs) on calpain activity measured in incubated erythrocytes. Data are mean± SEM
(n=8 in each group). Statistical analysis by one-way anova followed by Dunnett’s
multiple range test.

3.5.4 Discussions
In this work, we assessed the in vitro effects of PVP- and CT- AgNPs on mouse
erythrocytes and showed that AgNPs can induce hemolysis, oxidative stress and
increase cytosolic Ca2+, annexin V binding and calpain activity.
Our in vitro erythrocyte study is relevant to previous in vivo studies which
demonstrated that exposure to AgNPs is associated with cardiovascular dysfunction in
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addition to cytotoxicity and oxidative stress [73, 175]. We incubated the erythrocytes
with vehicle or PVP- or CT- AgNPs for 4 h; a time point similar to previous in vitro
studies [139, 279]. The various concentrations of PVP- and CT- AgNPs (2.5, 10 and
40 µg/ml) used in our study are also similar to previous studies evaluating nanotoxicity
and blood compatibility of erythrocytes incubated with AgNPs [141, 145]. Our
concentrations are comparable with previous studies using AgNPs on human, mouse
and fish erythrocytes and the highest dose of 40 µg/ml, is much lower than the optimal
dose of AgNPs (200 µg/ml) that has been reported to induce hemolysis in human
erythrocytes [139, 141, 145, 280-282]. In fact, in humans following oral exposure, in
vivo serum concentration of AgNPs of up to 10 µg/ml has been reported [283, 284].
The latter is within the range of concentrations of AgNPs that we used in our present
study. Both particle size and coating have been reported to play critical role in NPinduced toxicity; size <50 nm AgNPs induces greater hemolysis and increased uptake
by erythrocytes [47, 141, 145, 282]. Hence, we presently assessed the impact of 10 nm
AgNPs with 2 different coating, namely PVP and CT.
Our hemolytic assay results show that both 10 nm PVP- and CT- AgNPs cause
a dose-dependent hemolysis. Similar results were obtained when fish and human
erythrocytes were incubated with various sizes of AgNPs (15-100 nm); the highest
hemolytic activity being observed with size <50 nm AgNPs [139, 141]. Huang et al.
[145], in a study using human erythrocytes demonstrated that PVP- AgNPs (20 nm)
caused ~19% hemolysis while CT- AgNPs (20 nm) caused ~10% hemolysis at the
concentration of 40 µg/ml. Research focusing on TiO2 also showed evidence of
hemolysis in rabbit erythrocytes [285]. Our previous studies on interaction of
erythrocytes with DEP and amorphous SiNPs demonstrated significant dosedependent hemolysis [269, 271]. Besides using Triton X 100 as a positive control, we
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have also assessed the hemolytic effects of a positive control particle, namely
amorphous SiNPs (50 nm), at a dose of 25 µg/ml [269]. The latter results confirmed
the hemolytic effect of SiNPs (data not shown). The hemolytic activity of SiNPs
exposed erythrocytes has been demonstrated to be dependent on presence of negatively
charged silanol groups [286]. However, the mechanism by which AgNPs may induce
hemolysis is not fully understood. There is a strong body of evidence suggesting
interaction of RBC with AgNPs itself can induce hemolysis, rather than released silver
ion mediated cellular toxicity [139, 141]. It has been also stated that AgNPs can bind
to thiol groups within proteins or phospholipids of membrane with high affinity and
thereby promote denaturation [287]. Moreover, interaction of negatively charged
silver surface with cations in membrane of RBC may also contribute to hemolysis
[287].
To obtain more information about the possible uptake and localization of
AgNPs within RBCs, TEM analysis has been performed following incubation of
erythrocytes with various concentrations of AgNPs. Interestingly, both 10 nm PVPand CT- AgNPs were observed within the erythrocytes even at our lowest
concentration of AgNPs that is 2.5 µg/ml. The optimal size for uptake of AgNPs by
fish erythrocytes was reported to be ~50 nm [141]. However, despite the presence of
AgNPs in the erythrocytes the degree of hemolysis observed was relatively slight for
the concentrations of 2.5 µg/ml and 10 µg/ml for CT- AgNPs and concentration of 2.5
µg/ml for PVP- AgNPs. This could probably suggest that the hemolytic effect is both
coating and dose dependent. Our previous studies showed that DEP and SiNPs are
taken up by erythrocytes [269, 271]. Geiser et al. [288], in studies of TiO2 NPs on lung
cells and erythrocytes showed that particle uptake in cells was by diffusion or adhesive
interactions rather than endocytosis. However, it is well established that RBC’s lack
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endocytic machinery and there is no actin myosin system [289], and therefore the
mechanism underlying the uptake of nanoparticle by erythrocytes may be different
from other phagocytic cells. Though our study does not clearly define the mechanism
of entry of AgNPs into the cell it could be possible that, given their very small size,
the 10 nm AgNPs were able to enter the erythrocytes via diffusion as suggested before
[74]. Further studies are required to clarify this particular point.
To further clarify the possible mechanism related to hemolytic effect of PVPand CT- AgNPs, we assessed biomarkers of oxidative stress including MDA, GSH
concentration and CAT activity. MDA is one of the final products of polyunsaturated
fatty acid peroxidation in the cells and is used as a marker of cell membrane injury as
its production is increased with increase in free radicals [275]. Our data showed a dosedependent increase of MDA with significance at the highest concentration 40 µg/ml
for both PVP- and CT-AgNPs. Previous in vitro hemolytic studies also demonstrated
significant and dose-dependent increase in MDA in fish erythrocyte incubated with
AgNPs (15-100 nm) at various concentrations (1.25-20 µg/ml) [141]. However, our
previous study of interaction of DEP with erythrocytes demonstrated no significant
changes of MDA in mouse erythrocytes at 100 µg/ml [271]. In contrast, our other study
on interaction of erythrocytes with SiNPs showed significant MDA increase even at
25 µg/ml [269]. These results collectively indicate that the overproduction of MDA in
erythrocytes is particle and dose-dependent and that both studied coating (PVP and
CT) induce lipid peroxidation of RBC. Oxidative stress results from imbalance
between reactive oxygen species (ROS) and the antioxidant defense system.
Erythrocyte antioxidant enzymes are major circulating antioxidant enzymes in the
oxidative stress defense system [290]. GSH and CAT are major enzymes that control
the biological effect of ROS [290]. While GSH quenches the free radicals by serving
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as electron donor, CAT converts hydrogen peroxide to water and oxygen [291]. Our
data show, incubation with AgNPs results in significant decrease in GSH concentration
and CAT activity compared to control. The decrease of antioxidants in the present
study can be attributed to the increase of their consumption due to increase in ROS.
The activity of CAT has been shown to be decreased, and the concentrations of GSH
and MDA increased in trout hepatocytes incubated with selenomethionine [292]. The
data of our previous study showed a significant and dose - dependent increase in CAT
activity and GSH concentrations in erythrocytes treated with SiNPs [269]. The latter
effect has been explained by an adaptive response that counterbalances the potentially
damaging activity of free oxygen radicals by antioxidant defense mechanism [269].
Overall, these results indicate the relation between AgNPs interaction and alteration in
oxidative stress and antioxidant enzymes activities.
Mature erythrocytes are highly specialized cells that lack normal cell
organelles, such as nucleus and mitochondria, which are vital for the regulation of
apoptosis, an innate mechanism of cell clearance [293]. The senescence involved in
mature erythrocytes, is characterized by distinct changes in shape and plasma
membrane with translocation of phosphatidylserine from the inner leaflet of cell
membrane, and is termed as eryptosis [294, 295]. The later has been evaluated using
various techniques including cytofluorometric analysis [296]. However, unlike
apoptosis of erythroblast that is caspase - dependent, the mature erythrocyte is driven
into eryptosis by increase in intracellular calcium which in turn triggers activation of
calpain [295]. Apoptosis mediated cell death via AgNPs exposure has previously been
demonstrated in various cell line including normal human lung fibroblast,
glioblastoma and osteoblastic cells [297]. However, little is known about the
mechanism of cell death in AgNPs - treated erythrocytes. Our data shows significant
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and dose dependent increase of intracellular calcium and Annexin V binding for both
PVP- and CT- AgNPs. It has been shown that increased calcium activity is due to
activation of Ca2+ permeable cation channels which is, in turn, triggered by erythrocyte
injury including oxidative stress [294]. Additionally, typical features of eryptosis
including cell shrinkage, membrane blebbing, phosphatidylserine externalization has
been reported in erythrocytes exposed to Ca2+ ionophore ionomycin or A23187 [298,
299]. Annexin V is a Ca2+ dependent cellular protein that has the ability to bind with
phosphatidylserine and used as an apoptotic marker when exposed on outer leaflet of
cell membrane [298, 300]. Our present findings also corroborates our previous study
that demonstrated increased erythrocyte cytosolic calcium and annexin V binding
following incubation with SiNPs [269]. However, unlike the previous study, there
were no significant changes in caspase 3 activity compared to control except for CTAgNPs at concentration of 10 µg/ml. The discrepancy between the present and the
previous study could be related to type of NPs (PVP- and CT- AgNPs versus SiNPs)
and/or size of NPs (10 nm versus 50 nm). The caspase activity results were further
confirmed by western blot analysis, which also showed no significant changes in
expression of the total caspase 3 in erythrocytes exposed to various concentration of
PVP- or CT- AgNPs, compared with controls. Caspase members contain a cystine
residue and exists as zymogens that needs to undergo proteolytic cleavage before
inducing its initiator or effector function in apoptosis [301]. Though the presence of
caspase is well established in erythrocyte, their role in eryptosis is not clearly defined
[293]. Berg et al. [302] suggested that the inability of caspase activation in erythrocyte
might be due to presence of novel inhibitor or lack of other elements of apoptotic
machinery like Apaf1 and cytochrome C. Similar to caspases, another calcium
dependent cystine protease, calpains, exits as proenzymes and is reported to play a role
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in eryptosis [303]. Our data show that the incubation of erythrocytes with PVP- or
CT- AgNPs, results in significant increase in calpain activity compared with control,
and this increase could be attributed to the increase in cytosolic calcium. Our findings
corroborates with a previous study which demonstrated that changes in intracellular
calcium led to the activation of calpain [302].
To conclude, the interaction of two differently coated AgNPs was
comprehensively investigated in an in vitro model of mouse erythrocytes. We observed
that both PVP- and CT- AgNPs caused hemolysis and were taken up by the
erythrocytes at all tested concentrations. We also demonstrated that PVP- and CTAgNPs induced oxidative stress and increased cytosolic calcium, annexin V binding
and calpain activity which may explain the cause of hemolysis and mechanism by
which eryptosis may be triggered. More studies are required to further investigate the
mechanism underlying pathophysiological effects of AgNPs on eryptosis.
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Chapter 4: Conclusions, Limitations of study and Future directions
4.1 Conclusions
Owing to their antimicrobial properties AgNPs have become one of the most
popular types of NMs today. Like all NMs, AgNPs may pose a pulmonary and
systemic toxicity hazard should their level increase in air and translocate from the lung
to systemic circulation and various distant organs, a threat that has received inadequate
attention and that is the focus of our study. Collectively, this study investigated local
and systemic effects of pulmonary exposed 10 nm AgNPs of 2 coatings (PVP and CT),
3 doses (0.05, 0.5 and 5 mg/kg) and at 2 different time points (1 day and 7-days) in
Balb/C mice. We initially evaluated the cardiac effect of pulmonary exposed AgNPs
by measuring markers of inflammation, oxidative stress, DNA damage and apoptosis
in heart. Next, we evaluated the impact of AgNPs on coagulation by measuring several
endpoints, i.e., thrombosis in pial arterioles and venules in vivo, measurement of
plasma concentrations of fibrinogen, PAI-1, PT, aPTT and in vitro platelet
aggregation. Finding significant cardiovascular effects, we further studied the
biodistribution and pathophysiological effect of pulmonary exposed AgNPs on other
major organs including lung, liver, kidney, spleen and brain, by quantifying silver and
measuring markers of inflammation, oxidative stress, DNA damage and apoptosis.
Following translocation, a major component of systemic circulation with which NPs
may potentially interact with, is the erythrocytes. Hence, we also investigated in vitro
effect of 10 nm AgNPs of both coating (PVP and CT) and at 3 concentration (2.5, 10
and 40 µg/ml) on mouse erythrocytes. All the effects of AgNPs were compared with
control which are the diluents (0.9% NaCl and 2 mM citrate) used in our study as well
as Ag ions.
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The major findings in this thesis related to the studies described above are as
follows:
4.1.1 In vivo studies: Pulmonary exposure to AgNPs and pathophysiological
effects
4.1.1.1 Effect of coating
•

Both AgNPs, (PVP and CT) induced lung inflammation substantiated by
interstitial infiltration of inflammatory cells consisting of neutrophils,
lymphocytes and macrophages and the observed effects persisted after 7-days
of instillation.

•

PVP-AgNPs caused significant increase of TNF-α in lung and heart, CTAgNPs showed increase in heart, brain and liver. As for IL-6, CT-AgNPs
induced significant increase in lung, heart, brain and liver, while PVP-AgNPs
showed the increase in lung and heart. PVP- AgNPs caused more significant
increase in total antioxidants and GSH compared with CT-AgNPs in heart. As
for the other organs investigated, while CT-AgNPs showed increase of GSH in
lung, brain, kidney and spleen, PVP- AgNPs increased GSH in kidney and liver
following 1-day exposure. An increase of total NO was also observed with CTAgNPS in lung, brain and kidney, and PVP-AgNPs in liver. In case of marker
of lipid peroxidation, 8-isoprostane, CT- AgNPs induced a significant increase
in the lungs, heart and brain and PVP- AgNPs caused increase in lungs, heart
and liver.

•

With regard to markers of DNA damage and apoptosis measured, while CTAgNPs significantly increased 8-OH-dG in lung, heart and brain, PVP-AgNPs
increased in lung, heart and liver. Relatable to finding of 8-OH-dG level,
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significant increases of tunel positive cells were found in lung, heart and brain
with CT-AgNPs, and in lung, heart and liver with PVP-AgNPs.
•

Both coating AgNPs induced a significant shortening of the thrombotic
occlusion time in pial arterioles and venules, significant increase in the
concentrations of the coagulation factor, fibrinogen, PAI-1 and BNP in the
plasma. A significant shortening of PT and aPTT with both PVP- and CTAgNPs was observed suggesting that both intrinsic and extrinsic pathways may
be involved in the prothrombotic effects observed in vivo.

•

Both AgNPs induced in vitro platelet aggregation and thereby significantly
decreased platelet count at a dose of 1 µg/ml, which corresponds to 0.02% of
the highest instilled dose (5 mg/kg) in vivo.

•

Accumulation of silver post 1-day of i.t. instillation was observed in all the
organs examined with the highest in spleen and liver.

4.1.1.2 Effect of time
•

Inflammatory effects observed in H&E of lung post 1-day exposure persisted
after 7-days of instillation for both PVP and CT AgNPs. In case of proinflammatory markers, TNF-α in lung induced by PVP-AgNPs, persisted post
7-days of exposure. The oxidative stress effect declined 7-days post exposure,
except for total antioxidants in heart for both AgNPs type and NO in kidney
for CT- AgNPs. The increase of 8-OH-dG and tunel positive cells in heart
remained significant for PVP – AgNPs even after 7 days of exposure.

•

Significant shortening of the thrombotic occlusion time in pial arterioles and
venules were observed post 7-days of i.t. instillation, indicating that
prothrombotic effect of AgNPs persisted even after a week of exposure. The
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rise in BNP and decrease of PT and aPTT also persisted after 7 days of
exposure.
4.1.1.3 Effect of dose
•

Both PVP- and CT- AgNPs caused significant dose-dependent increase of
proinflammatory markers, oxidative stress, DNA damage and apoptosis and
significant dose dependent shortening of the thrombotic occlusion time in pial
arterioles and venules. However, the highest dose (5 mg/kg) resulted in more
toxic effects for both PVP- and CT- AgNPs in heart and plasma. Nevertheless,
some of the effects were significant at the lowest dose indicating that no effect
level could be much lower.

4.1.1.4 Distinct effect of Ag ions (ionic control)
•

Compared with histological findings of AgNPs, Ag+ ions produced a milder
inflammatory response in lungs consisting mainly of neutrophil polymorphs
and lymphocytes.

•

Unlike AgNPs, Ag+ ions induced significant increase of TNF-α and IL-6 in
kidney and spleen. While Ag+ ions increased GSH in spleen post 1-day
exposure, the ions significantly decreased GSH in heart post 7-days i.t.
instillation.

•

Ag+ ions caused significant increase of NO in lung and kidney, an increase of
8-isoprostane in spleen and liver; and an increase of 8-OH-dG and tunel
positive cells in lung and liver following 1 day after instillation.

•

Similar to AgNPs, Ag+ ions showed significant effect with respect to
thrombosis and concentration of fibrinogen. Contrarily to AgNPs, with Ag+
ions, PAI-1 showed significant increase at 7-days of exposure.
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•

With respect to Ag distribution, Ag+ ions were also distributed in different
tissues after single i.t. instillation.

4.1.2 In vitro studies: Effect of AgNPs on incubated mouse erythrocytes
•

Both PVP- and CT- AgNPs caused a significant concentration-dependent
hemolysis and were taken up by erythrocytes.

•

Both coating AgNPs induced oxidative stress as shown by significantly
increased MDA and decreased GSH and CAT activity.

•

Both PVP- and CT- AgNPs caused significant and dose dependent increase of
intracellular calcium, Annexin V binding and calpain activity which may
explain the cause of hemolysis and mechanism of eryptosis.

•

However, the degree of hemolysis varied between concentration (2.5, 10 and
40 µg/ml) and coatings of AgNPs.
To conclude, the influence of AgNPs (size 10 nm) with two distinct coating

(PVP and CT), three doses (0.05, 0.5 and 5 mg/dl) and two post exposure time points
(1 and 7-days) were comprehensively assessed in an in vivo model. Pulmonary
exposed PVP- and CT- AgNPs induced pro-inflammatory response and oxidative
stress in major organs including lung, heart, liver, kidney and brain, evidenced by an
increase of TNF-α, IL-6, GSH, total antioxidant, NO and 8-isoprostane, and caused
DNA damage, thereby reinforcing the previously established mechanisms of DNA
damage caused by reactive oxygen species and eventually resulting in cellular
dysfunction and apoptosis. The findings in our study indicate that lung exposed 10nm
AgNPs were translocated and distributed to the different tissues during the 1st day of
exposure either in the particle or ionic form. The overall pathophysiological effects
obtained herein by subsequent assays could be attributed to either the AgNPs
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themselves at the site of exposure or inflammation and oxidative stress induced in
lungs (site of deposition of AgNPs) or translocated AgNPs and markers of
inflammation and oxidative from the lung to the blood which subsequently can affect
distant organs (heart, liver, kidney, spleen and brain) or due to the release of Ag+ ions
or the combination of all the aforementioned mechanisms. Even though the release of
various markers investigated in this study varied between the particle types used and
the investigated organs, at least one or more than one marker of inflammation and
oxidative stress augmented in each studied organ, showing the occurrence of
inflammation and oxidative stress after single i.t. instillation of AgNPs. Some of the
acute effects observed persisted even after 7 days of instillation suggesting continuing
effect of AgNPs. The pattern of toxicity observed between AgNPs and Ag+ ions were
dissimilar possibly indicating that the effect obtained in our study may be related
primarily to AgNPs themselves rather than Ag+ ions. The difference observed in
pathophysiological effect in various organs also indicate that the particulate and ionic
form of silver may act by a different mechanism. With regard to dose, both particle
types showed a dose- dependent effect for some of the parameters measured. However,
PVP- AgNPs tended to induce a more significant effects at all doses compared with
CT- AgNPs. This study further revealed that these particles are able to induce DNA
damage and apoptosis in the brain possibly by crossing the blood-brain barrier in
particulate or ionic form after dissolution. Moreover, our in vitro study demonstrated
significant hemolysis and eryptosis by both PVP- and CT- AgNPs.
Overall, our results in this study suggest that application of AgNPs has to be
carefully considered with respect to size, dose, coating and duration of exposure. The
persistence of the pathophysiological effects following single i.t. administration and
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the fact that occupational and consumer exposure to AgNPs are not time limited,
necessitate the evaluation of the chronic effects of AgNPs exposure by inhalation.
4.2 Limitations of study
There were some limitations in our study including the use of both male and
female Balb/C mice for our work. Estrous cycle of female has been reported to have
an impact on vascular function and circulatory factors and we have not established the
stage during our in vivo experiments [260]. Moreover, our work did not differentiate
the effects observed between male and female, where gender difference in distribution
and toxicity of AgNPs have been reported previously [177, 204]. Moreover, although
our study characterized the particles thoroughly using TEM, zeta potential and size
distribution measurement, additional techniques can be applied to further characterize
AgNPs such as dynamic light scattering and UV-visible spectroscopy that provide
hydrodynamic diameter and intrinsic feature of possible aggregates of the particles,
respectively. Our work also lacked to evaluate the dissolution rates of AgNPs in vivo
as it is an important parameter needed for risk assessment [304]. Beside not having
appropriate evidence of the AgNPs like TEM within the organs where significant
pathophysiological effects were achieved, we were unable to conclude if the effect
observed were due to the particle itself or the Ag ions after dissolution.
4.3 Future directions
In this study, we were able to demonstrate that pulmonary exposed AgNPs,
either in particulate or ionic form, can induce pulmonary toxicity and cause
pathophysiological effect on vascular and distant organs including heart, liver, kidney,
spleen and brain. Data generated in our work added more to the growing evidence of
induced acute and remote toxicity following respiratory exposure to NPs based
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products. The persistence of the cardiovascular as well as other investigated organ
effects following single i.t. administration, and the fact that occupational and consumer
exposure to AgNPs are not time limited to 1-day, further researches are required to
evaluate the chronic effect of AgNPs exposure. The i.t. instillation used in the present
work has been shown to be a reliable, convenient and valid for certain objectives,
though admittedly not physiologically perfect, mode of administration of foreign
compounds into the airways. Additional studies using inhalation exposures are needed
to confirm our findings. Furthermore, it is well established that the impact of
particulate air pollution is aggravated in patients with pre-existing cardiorespiratory
diseases, for e.g., asthma, chronic respiratory diseases such as chronic obstructive
pulmonary disease, hypertension and ischemic heart diseases [305]. In this regard, the
impeding pathophysiological effects of AgNPs on susceptible populations can be
investigated in future studies using animal models of increased susceptibility, such as,
asthma, hypertension etc.
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